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INTRODUCTION 
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Dengue fever is a mosquito-borne tropical disease caused by the Dengue virus. 
Dengue fever virus (DENV) is an RNA virus of the family Flaviviridae; genus Flavivirus. 
Dengue is spread by several species of mosquito of the Aedes type, principally Ae. 
Aegypti and Ae.albopictus. 
Aedes female mosquitoes are the principal vectors for the transmission of Dengue 
virus. They have many characteristics that make them suitable for transmission of the 
virus
1,2
. Ae.Aegypti usually breed in or close to houses, laying eggs in both man-made 
and natural water containers and their flight distance is relatively short. Their post-blood 
meal flight distance was up to a maximum of 441m as proposed by Reiter et al. in 1995. 
They are daytime feeders that prefer to bite humans and are frequently unnoticed. They 
can easily move on to another host, frequently taking multiple blood meals in a single 
breeding cycle
3
. Thus, an infected A. Aegypti mosquito may transmit Dengue virus to 
several individuals in a small area. For these reasons, family members, typically women 
and young children are at particularly high risk for infection. They are widely distributed 
in tropical and subtropical areas from latitude 45º North to 35º South. 
Ae. albopictus mosquitoes, also called as Asian Tiger Mosquito. They  are also a 
competent vector for the transmission of Dengue virus under both experimental and 
natural conditions. Their usual flight distance is about 200m. They are more tolerant to 
cold and have a wider geographic distribution than Ae. Aegypti
4,5
. However, they are less 
likely to transmit since they do not bite humans as frequently as A. Aegypti and appear to 
be less efficient natural vectors for Dengue virus. Large outbreaks are rare in regions that 
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have Ae. albopictus. Both Ae. albopictus and A. Aegypti are also competent vectors for 
transmission of chikungunya virus and led to simultaneous outbreaks of both diseases in 
some areas
6
.Other Aedes mosquitoes appear to play an insignificant role in the global 
transmission of Dengue virus
7
. 
There are five closely related but serologically distinct Dengue viruses, called 
DENV-1, DENV-2, DENV-3, DENV-4 and DENV-5 of the genus Flavivirus. There is 
transient and weak cross-protection among the serotypes; therefore, individuals living in 
an area of endemic Dengue can be infected with different Dengue serotypes in a lifetime. 
Multiple virus serotypes often co-circulate within the same region (hyper endemicity), 
causing periodic epidemics. 
The symptoms of Dengue infection usually begin three to fourteen days after 
infection and they include a high fever, headache, vomiting, muscle, joint pains, and a 
characteristic skin rash. Recovery generally takes two to seven days. In few cases it 
develops into the life-threatening Dengue haemorrhagic fever leading to bleeding, low 
levels of blood platelets and blood plasma leakage, or into Dengue shock syndrome.
8,9
 
The diagnosis of Dengue fever may be confirmed by microbiological laboratory 
testing. This can be done by virus isolation in cell cultures, nucleic acid 
detection by PCR, viral antigen detection (such as for NS1) or specific antibodies (IgM 
and IgG serology). 
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AIM AND OBJECTIVES 
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AIM: 
 To identify the Dengue serotypes using molecular methods and its 
association with disease severity. 
OBJECTIVES: 
i) To find out the proportion of Dengue infection in fever patients in 
hospital 
ii) To classify primary and secondary Dengue.  
iii) To find out the serotypes prevalent here using multiplex-nested  PCR  
AND severity of the disease with serotypes. 
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REVIEW OF LITERATURE 
12 
 
HISTORY: 
The first case of Dengue fever was from the Jin Dynasty (265-420AD), referred to 
a „water poison‟ associated with the flying insects. The word Dengue may be derived 
from the Swahili phrase "Ka-dinga pepo", meaning "cramp-like seizure caused by an evil 
spirit". The word "Dinga" may have its origin from the Spanish word "Dengue" which 
means fastidious or careful, describing the gait of a person suffering the bone pain 
of Dengue fever
10
. 
Due to increased globalization secondary to slave trade there was an increase in 
the spread of Dengue in Africa during the 15
th
 to 19
th
 centuries. The first confirmed case 
report was in 1789 by Benjamin Rush, who coined the term "break bone fever" because 
of the symptoms of myalgia and arthralgia
11
. 
The primary vector, Aedes Aegypti leads to various epidemics from time to time. 
Transmission of Aedes mosquitoes was confirmed in 1906. Dengue was the second 
disease caused by a virus (after yellow fever). Ecological disruption leads to an increase 
in the marked spread of Dengue during the Second World War. The same trends led to 
the spread of different serotypes of Dengue virus to different areas and also to the 
emergence of Dengue haemorrhagic fever. This severe form was first reported in 
Philippines in 1953. In 1970s Dengue became the major cause of child mortality. First 
noted case of Dengue haemorrhagic fever and Dengue shock syndrome in central and 
South America was in 1981
12
. 
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The possible factors that lead to the spread of Dengue fever include, 
Overpopulation in unplanned urban areas leads to improper housing, water, sewage 
and waste management. Water stagnation leads to mosquito breeding and poor vector 
control. Changes in weather and evolution of virus leads to poor control of the 
disease.  Frequent travel to endemic areas leads to spread of infection. 
 DENGUE VIRAL STRUCTURE: 
The Dengue virion is a spherical particle existing as either a 50nm diameter 
immature 3 particle or a mature 60nm diameter particle. It has a lipopolysaccharide 
envelope. Dengue genome (11kb) has a single open reading frame and encodes three 
structural and seven non-structural proteins. The structural proteins are capsid(C), 
membrane (M), and envelope (E). The non-structural proteins include NS1, NS2A, 
NS2B, NS3, NS4A, NS4B and NS5 (Halstead 2008). The Dengue particle consists of the 
genomic RNA surrounded by the capsid, then the envelope with E and M proteins bound 
(zone 2012). Mature and immature viruses can be distinguished based on these proteins. 
The mature virus is referred to as „spiky‟ as M proteins bound to a precursor membrane 
protein (pr) form heterodimers with E proteins that appear as „spikes‟ on the viral surface. 
In mature virions the soluble pr is cleaved from M protein by furin, anchoring the M 
proteins and causing the pr protein to be absent in the mature viral membrane 
(Pokidysheva, Zhang et al.2008)
13,14
. 
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Figure 1: Dengue Virus Genomic Structure 
 
  
 
 
Figure 2: Morphology of Dengue Virus 
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PATHOGENESIS OF DENGUE: 
The disease manifest as in apparent clinical symptoms to severe manifestation like 
DHF/DSS due to multifactorial reasons. After the bite of infected female Aedes 
Aegypti/albopictus , the infected individuals develop disease varying  from 3 to12 days 
.These mainly depends on two major factors such as viral and host factors .Viral factors 
are viral virulence, viral tropism and antibody dependant enhancement. Host factors are 
age, sex, race, nutritional status, genetic factors, complement activation ,transient 
autoimmunity ,Cross reactive T cell response and Soluble factors. 
The virus inoculated into epidermal dendritic cells (DC)/immature Langerhans 
cells and keratinocytes which migrates to local lymph nodes. Monocytes and 
macrophages are directed at these sites. The infected monocytes and macrophages will 
enter into circulation resulting in primary viremia which causes infection in several cell 
lines of mononuclear lineage including blood derived monocytes, myeloid DC, splenic 
and liver macrophages
17,18
. 
During secondary infection with heterologous DENV infection, high concentration 
of specific immunoglobulin‟s will combine with newly produced virus that adhere to and 
taken up by the mononuclear cells. Following infection, these cells predominantly die by 
apoptosis and more viruses released into circulations. However partially 
infected/bystander DC are stimulated which produces bulk of inflammatory mediators 
and haemostatic response of the host
19,20
. 
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In spite of affecting several organs like spleen, liver, kidney, lungs and brain there 
is no microscopic evidence of organ pathology. It affects liver without causing 
morphological damage. Liver cells may die by apoptosis without any inflammation
21
. 
Endothelial cells (EC) have an important role in coagulation response with severe 
systemic Dengue infection.EC do not carry FCγR on their surface so it will not take up 
antibody coated virus. However lung and abdominal vasculature may contain virus by 
pinocytosis
22
 .Infection in these cells produces no morphological damage, only causes 
functional damage.NS1binds to EC of pulmonary and hepatic tissues .Selective apoptosis 
of micro vasculature in lung and intestinal tissues leads to plasma leakage and fluid 
collection seen in pleural and peritoneal cavity
23
. 
DENV has 5 serotypes (ST) and many genotypes. Viral genetic difference is 
associated with differences in virulence. It evolves during an epidemic into a severe form 
of strain by continuous passage. High incidence of severe Dengue infection is seen in 
secondary infections with DENV-2 and DENV-3 following DENV -1 infection. The 
incidence of disease severity increases if longer the interval between primary and 
secondary infection. Severe infections in children are observed in Asia but in America 
adult population are mostly affected. Black people have more protection than white 
people. Males are more affected than females and children
24,25
. 
Activation of complement is an important role in pathogenesis of Dengue. 
Complement is activated by binding of heterotypic antibody to NS1 antigen which is 
expressed on infected cells.C5b-C9 complex stimulate the production of inflammatory 
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cytokines responsible for activation of coagulation system which is associated with 
DHF/DSS. Coagulation enzymes and IgG1, IgG3 also effectively activates the 
complement system
25,26
. 
In transient autoimmunity cross reaction of anti NS1 antibody with cells of liver, 
platelets and EC is observed. NO (nitric oxide) is produced from EC which undergo 
apoptosis and leads to plasma leakage.NO production inhibit DENV replication and its 
over production leads to cell damage
27
. Transient thrombocytopenia caused by anti NS1 
antibodies cross react with platelets. So there was a controversy in production of live 
attenuated vaccines. These antibodies also enhances expression of I-L6, IL-8 and ICAM-
1(intra cellular adhesion molecule)
28
. 
In cross reactive T cell response,CD8+ T cells with high avidity for infecting virus 
secretes high concentration of  pro and anti-inflammatory cytokines such as IFNγ, TNFα 
and IL-13 but low levels of IL-10. These high avidity cross reactive CD8+ Tcells die by 
apoptosis. Alternatively low avidity CD8+ T cells for heterologous virus expand to 
produce high level of pro inflammatory cytokines but lose their cytolytic activity. Due to 
increased frequency and higher activation state cross-reactive memory T cells for the 
primary infecting virus are effectively activated. This phenomenon is called “Original 
antigenic sin”(OAS).It is based on TCR(Tcell receptor) variation in different 
individuals
29,30
. 
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Host genetic factors constitute an important component in the susceptibility of 
disease in both individual and population level. DHF is associated with several HLA 
class I, Π alleles and polymorphism in TNFα, FcγR,Vitamin D receptor,CTLA-4,DC-
SIGN and TGFβ. Individuals with G6PD deficiency have decreased NO,H2O2 and super 
oxide production which can increase viral proliferation and viral virulence. MBL-2 leads 
to thrombocytopenia in DHF
31
. 
Soluble factors are associated with severe DHF/DSS. A “storm” of inflammatory 
cytokines and other mediators are secreted by an increase viral load and non protective T 
cells in host leading to increased plasma leakage characteristic of DHF/DSS.Increased 
levels of IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8,IL-10, IL-13, IL-18, TGF-α, TNF-1β , and 
IFN-γ are seen in severe disease32,33. Multiple cytokines contribute simultaneously in a 
complex way to the development of DHF/DSS. DSS patients recover rapidly as cytokines 
do not cause tissue destruction and reversal of EC dysfunction. 
The soluble factor Thrombin converts fibrinogen to fibrin and triggers platelet 
activation .These activated platelets release a soluble factor called MMP9 which 
enhances easy permeability leading to plasma leakage and edema
34
. Thrombin also 
activates complement factors such asC3a and C5a enhancing blood thrombogenicity 
.Thrombin stimulates the production of IL-10   by monocytes. This IL10 inhibits 
expression of Tissue factor (TF) fibrinolysis.   IL-6 is a potent inducer of fever .Due to 
EC damage in the liver, IL8 is also abundantly produced . IL-8 induces the expression of 
adhesion molecules ICAM-1 and VCAM-1. TNF-α enhances capillary permeability and 
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activates the fibrinolytic system .It enhances the expression of  NO which induces 
apoptosis of cells and  also enhances vasodilatation leading to edema formation. TNF-α  
mediates death of  T cells leading to peripheral T cell deletion .TGF-β, late in the 
infection ,enhances the production of Th2 cytokines such as IL-10 and inhibits 
Th1response.Activation of  vascular endothelial growth factor (VEGF) will also increases 
vascular permeability
35
. 
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Figure 3: Pathophysiology of Dengue 
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BIOMARKERS FOR PREDICTION OF DENGUE SEVERITY: 
Biomarkers help in the prediction of severe Dengue in patients without any 
warning signs. An ideal biomarker should be able to identify individuals who are at risk 
of developing severe Dengue. There are four types of biomarkers 
 Immune activation markers   
 Endothelial activation markers 
 Biochemical markers 
 Genetic markers 
The advantages of these biomarkers include accuracy and helps in providing early 
supportive care. The disadvantages include cost, requirement of sophisticated instruments 
and altered levels may be seen in other diseases also
36
.  
Table1: Biomarkers of severe Dengue disease 
Class Biomarker Change 
1. Immune activation 
markers 
Cells Plasmacytoid dendritic 
cells 
Decrease 
Lymphocytes Decrease 
Platelets Decrease 
Cytokines IL-10 Increase 
MIF Increase 
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Class Biomarker Change 
Chemokines CXCL-10 Increase 
Complements C3a, C5a Increase 
Soluble receptors sCD4/8, sIL-2R, 
sTNFRII 
Increase 
Proteases Tryptase and chymase Increase 
2. Endothelial activation 
markers 
Mediators of endothelial Angiopoietin-1 Decrease 
function Angiopoietin-2 Increase 
Coagulation pathway von Willebrand factor Increase 
components ADAMTS-13 Decrease 
sThrombomodulin Increase 
Cell surface adhesion 
molecules 
sICAM, sVCAM Increase 
Permeability mediators VEGF, VEGFRI Increase 
 VEGFRII Decrease 
3. Biochemical markers Lipids Total cholesterol, HDL, 
LDL 
Decrease 
LPS LPB, CD14 Increase 
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Class Biomarker Change 
Liver enzymes AST, ALT Increase 
Serine protease IaIp Decrease 
Other soluble substances Nitric oxide Decrease 
4. Genetic markers Gene profile Certain gene expression Decrease 
Circulating cell free-
DNA 
 Increase 
 
DIFFERENTIAL DIAGNOSIS: 
The differential diagnosis of Dengue fever varies by country, region, season 
specific and includes Measles, Rubella, Enterovirus, Influenza, Typhoid, Chikungunya, 
Scarlet fever, Malaria, Leptospirosis, Hepatitis A, Rickettsiosis, Bacterial sepsis, Other 
viral hemorrhagic fevers- Ebola, Lassa fever, West nile fever, Rift valley fever. 
EPIDEMIOLOGY OF DENGUE: 
SEROTYPES: 
There are four closely related but serologically distinct Dengue viruses, named 
DENV-1, DENV-2, DENV-3 and DENV-4, belongs to the genus Flavivirus. The fifth 
and the latest serotype have been declared in October 2013, called DENV-5. This 
serotype was found in the sample of a 37 year old farmer from Sarawak state of Malaysia 
24 
 
in 2007
79
. The first four serotypes exhibit transient and weak cross protection among 
themselves, therefore in an endemic area individuals can be infected with up to four 
serotypes in a lifetime. There may be hyperendemicity in a region leading to periodic 
epidemics. Initially DENV-5 was thought to be a variant of Dengue 4 serotype, but 
infection in the rhesus monkeys that were previously infected with other four serotypes 
leads to significantly different set of antibodies. This proved that the new virus was 
indeed a new serotype and not a variant of DENV-4
15,16
.  
DENGUE IN INDIA: 
Dengue viruses have been persisting in India year after year since 1956. In 
Tamilnadu, the first major outbreak of Dengue was noticed in Vellore, South Arcot 
district in 1961 and the viral etiology was established later by the isolation of Dengue 
virus (Carey et al., 1966). The first virologically proved epidemic of Dengue fever in 
India occurred in Calcutta and eastern coast of India in 1963 - 1964 (Sarkar et al., 1964; 
Chatterjee et al., 1965; Carey et al., 1966). Then, the Dengue infection spread northwards 
and reached Delhi in 1967 (Balaya et al., 1969). Subsequently, the whole country was 
involved with widespread epidemics followed by endemic or hyper endemic prevalence 
of all four serotypes of Dengue virus. After the occurrence of first epidemic in 1961, 
Vellore experienced outbreaks in the year 1964, 1966 and 1968. The virological 
investigations carried out during that period proved the presence of Dengue 2 in 1964 
outbreak (De Ranitz et al., 1965; Carey et al., 1969). Dengue 3 virus was isolated in 1966 
outbreak (Myer et al., 1969) and all four types of Dengue virus in 1968 outbreak (Myer et 
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al., 1970). The epidemic at Vishakapatnam in 1964 was due to Dengue 2 virus 
(Krishnamurthy et al., 1965; Paul et al., 1965). The epidemic of Dengue in Nagpur in 
1965 documented the presence of Dengue 4 virus in that region (Rodrigues et al., 1972). 
In the same year, another outbreak was observed in Madras(now Chennai) which was 
caused by Dengue 3 viruses (Myers et al., 1968). Later, outbreaks of Dengue occurred in 
Jabalpur (MP) by Dengue virus 3 in 1966 (Sehgal et al., 1967, Rodrigues et al., 1973) in 
Asansol in 1967 by Dengue 2 and 4, in Delhi in 1967 by Dengue 2 (Balya et al., 1969), in 
Kanpur in 1968 and 1969 by Dengue 4 and Dengue 2 (Chaturvedi et al.,1970 ; 
Chaturvedi et al.,1972), in Ajmeer in 1969 by Dengue 1 and Dengue 3 (Ghosh et al., 
1974), in 12 Gwalior in 1970 by Dengue 3 (Arora et al., 1970), in Bangalore in 1971 by 
Dengue 1 and Dengue 2 (George and Soman, 1975 ); (Raghavan et al.,1970) in Jaipur in 
1971 and 1973 by Dengue 1 and 2 (Padbiri et al., 1973; Mathew et al., 1976), in Jammu 
in 1974 by Dengue 2 (Mathew et al., 1977) and in Trichur in 1974 by Dengue 2 
(Sreenivasan et al.,1979). Dengue 3 has been isolated during the epidemic at Calcutta in 
1983 (Mukerjee et al., 1987). An epidemic of Dengue at Rajasthan in 1985 was due to 
Dengue 3 virus (Chouhan et al., 1990). Dengue 2 was isolated during the epidemics of 
Dengue in urban and rural areas of Gujarat state during 1988 and 1989 (Mahadev et al., 
1993). Outbreaks occurred at Gwalior in 2003 and 2004 by Dengue 3 (Dash et al., 2005, 
2006). Padbiri et al., (1995) reported Dengue in Mangalore, Karnataka in 1993. In 
Punjab, there was an outbreak of Dengue in 1996 (Kuldip et al., 1997). The outbreak of 
Dengue in Delhi in 1996 was due to Dengue 2 (Chusak et al., 1993; Dar et al., 1999). 
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Hence, the presence of all four types of Dengue virus and occurrence of the disease all 
over the India were well documented.  
 DENGUE IN TAMILNADU: 
As stated earlier, in Tamilnadu, the outbreaks of Dengue were noticed in Vellore, 
North Arcot district in 1961 (Carey et al., 1964, 1966 and 1968; Carey et al., 1969; Myers 
et al., 1970). During this period, an outbreak was also noticed in Madras (Chennai) in 
1965 (Myers et al., 1968). The occurrence of Dengue fever was reported in villages in 
Dharmapuri district, Tamilnadu in 1997 (Kader et al., 1997) and in 2001 (Victor et al., 
2002). The presence of Dengue fever for the first time in Coimbatore and Erode district 
of Tamilnadu was reported during 1998 by Singh et al .,(2000). There was an outbreak of 
Dengue in Chennai in 2001 which was caused by Dengue 2 and Dengue 3 viruses. 
(Kabilan et al., 2005). The outbreak of Dengue in Kanyakumari district in July 2003 
proved the presence of Dengue serotype 3 virus in that area (Paramasivam et al., 2006). 
CLINICAL FEATURES OF DENGUE INFECTION: 
The typical clinical manifestation of Dengue infection range from self limiting 
Dengue fever to Dengue haemorrhagic fever with shock syndrome. 
ASYMPTOMATIC INFECTION: 
Most of the Dengue virus infections in adults are symptomatic as compared to 
children under the age of 15 who are asymptomatic or minimally symptomatic
37
. 
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CLASSICAL DENGUE FEVER: 
It is an acute febrile illness characterized by headache, retro orbital pain and 
severe muscle, joint pains (break bone fever). Clinical symptoms usually begin between 4 
and 7 days after the mosquito bite. The incubation period may range from 3 to 14 days. 
Fever classically lasts for five to seven days, with a biphasic curve in some patients 
(saddleback), with the second febrile phase lasting for one to two days. Febrile phase may 
be followed by a phase of marked fatigue that can last for days to weeks. Symptoms have 
age and sex predilection. All symptoms were less frequent in patients less than 19 years 
of age. Females have joint pain, body aches and rashes. Rashes were commonly seen 
during primary infection, whereas constitutional and gastrointestinal symptoms were 
common in secondary infection. Rashes were seen 2 to 5 days after the onset of 
fever
38,39,40
. 
HAEMORRHAGIC MANIFESTATIONS: 
Haemorrhagic manifestations occur commonly in Dengue and can be life 
threatening rarely. The common bleeding sites are skin, nose and gastrointestinal system 
in descending order
41
. 
OTHER SYMPTOMS: 
a) Constitutional symptoms, including fever 
b) Headache, retro orbital pain, body ache, and joint pain 
c) Rash  
d) Nausea, vomiting and diarrhoea 
28 
 
e) Cough, sore throat, nasal congestion42. 
Table 2: Common Clinical Features of Dengue (WHO:2009) 
Clinical Symptoms Number of Cases (%) 
Fever 100 
Thrombocytopenia 77 
Maculopapular Rash 31 
Elevated Liver Enzymes 51 
Vomiting 35 
Headache 26 
Arthralgia/ Myalgia 32 
Bleeding Manifestation 25 
Pain Abdomen 18 
Conjucntival Congestion 10 
Respiratory Complaints 11 
Neurological Complaints 10 
Hypotension 8 
Diarrhoea 9 
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WHO CLASSIFICATION OF DENGUE: 
There are two classification systems for Dengue infection depending on the 
clinical status. They are called Old (1997) classification and New (2009) classification. 
 
OLD CLASSIFICATION (1997): 
Figure 4: Old Dengue Classification 
 
 
NEW CLASSIFICATION (2009): 
The WHO special program for research and training in tropical diseases and the 
Pan-American health organization proposed a revised classification system in 2009
43
. 
Based on this classification there are two broad categories: 
1) Non severe Dengue 
2) Severe Dengue 
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Non severe Dengue can be further divided into Dengue with or without „warning signs‟ 
which includes 
a) Abdominal pain or tenderness 
b) Persistent vomiting 
c) Clinical signs of fluid accumulation 
d) Mucosal bleeding 
e) Lethargy or restlessness 
f) Liver enlargement >2cm 
g) Increase in haematocrit concurrent with rapid decrease in platelet count 
The term „Severe Dengue‟ can be applied to the patients with following features 
a) Severe plasma leakage- leading to shock or fluid accumulation with respiratory 
distress 
b) Severe haemorrhage (as defined by the treating physician) 
c) Severe organ impairment (AST or ALT>1000, impaired consciousness, severe 
involvement of heart or other organs)  
PHYSICAL EXAMINATION: 
Conjunctival injection, pharyngeal erythema, lymphadenopathy, hepatomegaly, 
facial puffiness and palatal petechiae. Rash is typically macular or maculopapular and 
may be associated with pruritis
44
. 
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LABORATORY FINDINGS: 
a) Leukopenia- common in children and adults 
b) Thrombocytopenia – platelet<100,000 cells/cu.mm 
c) Elevated serum aspartate transaminase- both in adults and children45. 
DENGUE HAEMORRHAGIC FEVER: 
It is the most dreadful complication of Dengue fever and is associated with 
circulatory failure and shock. The four cardinal features are 
a) Increased vascular permeability- plasma leakage syndrome- characterized by 
hemoconcentration (20% or greater rise in haematocrit above the baseline value), 
pleural effusion or ascites. 
b) Marked thrombocytopenia- platelet<100000cells/cu.mm 
c) Fever lasting for 2 to 7 days. 
d) Haemorrhagic tendency or spontaneous bleeding45. 
When these features are associated with shock, the term Dengue shock syndrome is used. 
PLASMA LEAKAGE: 
It is the most specific and life threatening feature of Dengue haemorrhagic fever. 
Increased vascular permeability can develop over a period of 24 to 48 hours. Marked 
plasma leakage leads to shock in case of delayed supportive measures. It usually occurs 
between 3 to 7 days after the onset of illness. This will coincide with defervescence, 
severe thrombocytopenia and elevated aminotransferases. Abdominal pain, persistent 
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vomiting, marked restlessness or lethargy and coincidence with defervescence should 
raise the suspicion of impending DSS. Imaging is needed for detection of pleural effusion 
and ascites
45,46
. 
HAEMORRHAGIC MANIFESTATIONS: 
The features include spontaneous petechiae or ecchymoses, hematemesis, malena, 
menorrhagia and epistaxis
46
. Positive tourniquet test demonstrates microvascular 
fragility. This is done by inflating a blood pressure cuff on the arm to midway between 
systolic and diastolic blood pressures for five minutes. The pressure is released for at 
least one minute and the skin below the cuff is examined for petechiae. A finding of 10 or 
more petechiae in a one square inch area is considered positive. 
OTHER MANIFESTATIONS: 
Liver failure may be caused by prolonged hypo perfusion or hypoxia rather than a 
direct viral effect. 
Neurological manifestations include encephalopathy and seizures. Symptoms 
include fever, headache and lethargy. Other associated neurological syndromes are acute 
pure motor weakness, mononeuropathies, polyneuropathies, Guillain-Barre syndrome and 
transverse myelitis. Reye syndrome has been seen in children associated with use of 
salicylate medications rather than Dengue infection per se
47
. 
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Myocardial dysfunction has been seen in hospitalized patients. It may be due to 
the fluid overload while treating shock. Elevated Troponin-I or the N terminal fragment 
of B-type natriuretic peptide may be seen.  
Acute kidney injury has been reported. It may be due to the complication of shock, 
or due to rhabdomyolysis, glomerulonephritis and acute tubular necrosis
48
. 
Other rare manifestations include cholecystitis and retinal vasculitis. 
Hemophagocytic lymphohistiocytosis may be associated with Dengue fever
49
. 
Based on these data it was concluded that the vaccine may yield a public health 
benefit, though the durability of vaccine impact and level of herd immunity required to 
affect Dengue transmission are both unknown. According to WHO strategic advisory 
group of experts the vaccine should be introduced only in geographic settings with 
seroprevalence> 70% in the target age group. It should not be used if the seroprevalence 
is <50%. 
LABORATORY DIAGNOSIS: 
The laboratory diagnosis of Dengue infection is based on the following Direct and 
indirect methods. Directs methods are detection of RNA in serum or tissues, virus 
isolation and detection of viral antigens(NS1).Indirect methods are detection of specific 
antibodies in serum(IgM & IgG).If the test has high accessibility, the confidence interval 
is low(Indirect methods) but if the test has low accessibility the confidence interval is 
high(Direct methods). 
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VIRUS ISOLATION: 
The following methods can be used for isolation of Dengue viruses by 
intracerebral inoculation of new born mice, Inoculation on mammalian cell cultures, 
intrathoracic inoculation of adult mosquitoes and Inoculation on mosquito cell 
cultures
50,51
. 
INTRACEREBRAL INOCULATION: 
All the four serotypes can be isolated by intracerebral inoculation of suckling 
mice
52,53,54
. The limitations are high cost, long time for isolation and low sensitivity. 
MAMMALIAN CELL CULTURE: 
In this culture, the viruses frequently require multiple passages before inducing 
cytopathic effects in infected cells. They also have limitations like that of intracerebral 
inoculation, hence not routinely recommended for virus isolation
51
. LLCMK2(monkey 
kidney), Vero(monkey kidney), BHK21(baby hamster kidney) are examples of 
mammalian cell lines. 
MOSQUITO INOCULATION: 
It is the most sensitive but least used method for virus isolation
55
. The mosquito 
species used are Aedes Aegypti, A.albopictus ,Toxorhynchitiesamboinensis and 
T.splendens. Both male and female mosquitoes can be used. Mosquito tissues like brain, 
salivary glands and intrathoracic inoculation can be used. DengueDengue viruses 
replicate in high titres within four to five days after appropriate incubation and detected 
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by immunofluorescence assay (IFA). The limitations are need for insectaries to produce 
large number of mosquitoes, hard work and isolation precautions to prevent the release of 
infected mosquitoes
56,57
. 
MOSQUITO CELL CULTURE: 
It is the latest method for virus isolation. The most widely used cell lines are 
Aedes Aegypti, A.albopictus(C6/36) , Toxorhynchities amboinensis(Tra-284) and 
T.splendens, A.pseudoscutellaris(AP61,AP64 and CLA-1) .The Dengue antigens in the 
infected cell culture can be detected by immunofluorescence assay. Advantage is rapid, 
sensitive and economical. It is more sensitive than vertebrate culture system, easy to 
maintain and grow at room temperature, can kept for 14 days without a change of growth 
medium and carried into the field and inoculated directly with human serum
58,59,60
. 
NUCLEIC ACID DETECTION: 
These methods can readily detect Dengue viruses during the acute phase and 
sometimes during the convalescence phase. The methods used are  
 Nucleic acid hybridization 
 Reverse transcription- polymerase chain reaction 
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NUCLEIC ACID HYBRIDIZATION: 
In nucleic acid hybridization, the RNA extracted either from Dengue virus 
infected cell culture supernatants or pools of infected A.albopticus are hybridized either 
with biotinylated probes or 32P- labelled probes
61
. Methods using biotinylated probes are 
less sensitive than radiolabelled probes. It is primarily used in epidemiological studies. 
RNA-RNA hybridization is a sensitive method that can be applied directly on 
fresh samples or on retrospective analyses of fixed samples. It is more often used as a 
research tool
62,63
. 
RT PCR: 
It offers better sensitivity than virus isolation with a rapid turnaround time. Best 
clinical sample for RT-PCR is serum/plasma while compared to other human clinical 
samples, biopsies, autopsy tissues or mosquitoes. It involves three basic steps nucleic 
acid extraction and purification, amplification of the nucleic acid, detection and 
characterization of the amplified product.  
Extraction and purification of viral RNA from the specimen can be done by QIA 
amp Viral RNA kit(automated magnetic bead based) or by a liquid phase separation 
methods (phenol/ chloroform), or by solid silica based commercial kits (column 
based).Its results are based on region of the genome amplified and primer are used to 
achieve this goal. Lanciotti et al developed consensual primers (D1&D2) which amplify 
at 511bp fragment of C and prM genes of Dengue in conventional RT-PCR, after that 
agarose gel electrophoresis is done to identify the amplified product of 511bp fragment to 
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confirm DENV infection. The sensitivity of this test varies from 80 to 100%. False 
positives can occur as a result of contamination by amplicons from previous 
amplifications
64,65,66
. 
NESTED PCR: 
Detection of Dengue virus is three to four fold increased by using nested-PCR.It 
can be type specific for Dengue serotyping (DENV1-4) with detection threshold of less 
than 100 PFU. In nested PCR assay, universal Dengue primers are used targeting the 
C/prM region of the genome. Double-stranded DNA product of the RT-PCR was typed 
by a second round of PCR amplification (nested PCR) with type-specific primers, which 
yielded DNA products, the unique sizes of which were diagnostic for each Dengue virus 
serotype (TS1-482bp, TS2-119bp, TS3-290bp, TS4-392bp).This amplified products  are 
identified by using agarose gel electrophoresis
65
. 
ONE-STEP MULTIPLEX PCR: 
It is an alternative to nested PCR in which there is a combination of four serotype 
specific oligonucleotide primers in a single reaction tube. The products of these reactions 
are separated by agarose gel electrophoresis and the amplification products are visualized 
as bands of different molecular in the gel using ethidium bromide dye
67
.  
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REAL-TIME RT PCR: 
It is a one-step assay system for quantification of viral RNA using primer pairs 
and probes that are specific to each Dengue serotype. Fluorescent probe enables the 
detection of reaction products in real time in a specialized PCR machine. The assays that 
have been developed are TaqMan or SYBR Green technologies. Off which TaqMan 
assay is highly specific due to the sequence specific hybridization of the probe
67
. 
Real-time RT PCR assays can be either singleplex or multiplex. The multiplex 
assays can detect all four serotypes in a single reaction without introduction of 
contamination. Advantages are rapidity, ability to provide quantitative measurements, 
lower contamination rate, easy to standardize, higher sensitivity and specificity. They are 
less sensitive than nested PCR assays
67
. 
NASBA: 
Nucleic acid sequence based amplification assay is an isothermal (41˚C) RNA 
specific amplification that does not require thermal cycling instrumentation. The first step 
is a reverse transcription in which the single stranded RNA target is copied into a double 
stranded DNA molecule that serves as a template for RNA transcription. Detection of 
amplified RNA is done by electrochemiluminescence or in a real time by fluorescent 
labelled molecular beacon probes. It has sensitivity as that of virus isolation
68
. 
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RT-LAMP: 
This loop mediated isothermal amplification assay detects 3‟noncoding region  of 
DENV serotypes. It is simple, rapid and amplification can be obtained in 30 minutes at 
isothermal condition (63˚C). 
NUCLEOTIDE SEQUENCING AND PHYLOGENETIC ANALYSIS: 
Nucleotide sequencing of the C-prM gene junction of DENV is carried out by Big 
Dye Terminator Cycle Sequencing Ready Reaction Kit with ABI 3100 sequencer 
(Applied Biosystem, USA) for identifying genotype of DENV serotypes by standard 
protocol. The sequence is entered into BLAST to identify the close sequence. By using 
Neighbour Joining (NJ) method of MEGA3 software version, the phylogenetic analysis is 
done based on C-prM gene junction of serotypes by including a large number of 
geographically diverse DENV gene sequences. It is mainly used in outbreak to identify 
origin of serotypes by using phylogenetic tree generated by NJ method
64
. 
DETECTION OF NS1 ANTIGEN: 
NS1 is a 50kDa glycoprotein synthesized by all flaviviruses. During acute phase 
of infection, NS1 protein is secreted by Dengue virus and found associated with 
intracellular organelles or it is transported through the cellular secretory pathway to the 
cell surface. This hexameric form is released from infected mammalian cells but not from 
vector derived mosquito cells. Presence of high concentrations of hexameric form of NS1 
antigen indicates impending risk of severe Dengue.it is detectable from day 1 to day 18 
but peak at day 1 to7. 
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Dengue NS1 Ag MICROLISA is an in vitro test for detection of  NS1antigen in 
serum or plasma. It is a solid phase ELISA based on the direct sandwich principle. Only 
human serum or plasma should be used. Specimens should be free of microbial 
contamination and stored at 2 to 8˚C for one week or can be frozen at -20‟C. Repeated 
freezing and thawing should be avoided. 
The micro wells used in this test are coated with anti-Dengue NS1 antibodies with 
high reactivity for Dengue NS1 antigen. The samples are added to the wells followed by 
addition of enzyme conjugate (monoclonal anti Dengue NS1antibodies linked to 
horseradish peroxidase). A sandwich complex is formed in the well wherein Dengue NS1 
is trapped or sandwiched between the antibody and antibody HRPO conjugate. Unbound 
conjugate is washed off with wash buffer. The amount of bound peroxidase is 
proportional to the concentration of NS1 antigen present in the sample. Addition of the 
substrate buffer and chromogen leads to development of blue colour. The intensity of the 
colour is proportional to the concentration of antigen in the sample. To limit the enzyme-
substrate reaction, stop solution is added and a yellow colour develops which is read at 
450nm spectrophotometrically. 
If the Dengue NS1 Ag units is <9, then the sample is negative for Dengue. If 
between 9 to 11 units, then the test in equivocal. If >11 units, the sample is positive for 
NS1 antigen. The sensitivity of this test is 99.5% and specificity is 100%. 
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Limitations of this test are, used for NS1 antigen detection only in serum or 
plasma, it‟s a screening test only and false positive results can occur due to its cross 
reactivity
69
.  
SEROLOGICAL DIAGNOSIS: 
The serological tests used for the diagnosis of Dengue infection includes 
 Haemagglutination inhibition(HAI), 
 Complement fixation Test (CFT), 
 Plaque reduction Neutralization test(PRNT), 
 Indirect immunofluorescent-antibody test 
 Immunoglobulin M (IgM) capture enzyme linked immunosorbent assay 
(MAC-ELISA), 
 Indirect immunoglobulin G(IgG) capture ELISA, 
 Dot blotting, 
 Western blotting, 
 Rapid immunochromatography test 
HAEMAGGLUTINATION INHIBITION (HAI): 
This test was introduced by Sabin and colleagues and modified by Casals and 
Brown. It was used as a standard diagnostic method for the diagnosis of Dengue due to 
its high sensitivity and ease of use. It was used in seroepidemiological studies and to 
differentiate primary and secondary Dengue infections. Dengue viruses agglutinate 
gander erythrocytes and trypsinized type O human red blood cells. The HI test is based 
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on the ability of the Dengue virus antibodies to inhibit this agglutination. The procedure 
is carried out in the following steps. 
 Sera should be extracted with kaolin or acetone and adsorbed with gander or 
trypsinized type O red blood cells 
 All wells in micro titre plate receive 0.025ml containing 8-16 HA units of each 
Dengue antigen. Plates are covered and incubated at 4 degree C overnight. 
 Next morning plates are kept in room temperature, 0.05ml of an 8% goose red cell 
stock solution diluted 1:24 in the proper pH buffer is added to each well. Plates are 
observed for one hour and agglutination scored. 
 All sera from a single patient should be tested in the same assay. As a screening test 
a single antigen may be used (DENV-1 or 4) with little loss of sensitivity in primary 
infections. If the screening test for paired sera is negative, the specimens may be 
retested against all Dengue antigens. Known positive and negative sera should be 
included in each test to standardize the results and to maintain quality control.  
 In primary infections the antibodies are detected from fifth or sixth day of symptoms 
when the titres are above 1:10. The antibody titres are also low in convalescent sera 
(1:640) in primary infections. On the other hand the antibodies are detected very 
early in secondary or tertiary infections, usually higher than 5:120. Thus, a higher 
titre of antibodies (1:1280) during the acute phase or at the beginning of 
convalescent phase of disease is an indication of secondary infection
70
. The 
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limitations of this test are its lack of specificity, need for paired samples and 
inability to identify the serotype. 
Table 3: WHO criteria for interpreting HI assay results
 
COMPLEMENT FIXATION TEST: 
This test is not routinely used for the diagnosis of Dengue infection. It is based on 
the principle that complement will be consumed during antigen-antibody reaction. The 
antibodies usually appear later than HI antibodies and also persist for short periods and 
hence they have limited value in seroepidemiological studies. They are very specific in 
primary infections and contributes to the identification of infecting serotype. The 
limitations of this study are requirement of trained personnel and difficult to perform
71,72
. 
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PLAQUE REDUCTION NEUTRALIZATION TEST 
This test was developed by Halstead, Nisalak and Sukhavachana. This assay was 
developed to measure the DENV neutralizing antibody and uses “probit analysis” to 
measure plaque reduction at a 50% endpoint (PRNT50). It is the gold standard test for 
measuring Dengue antibodies. 
Few variations in this technique were introduced, such as a micro metabolic 
inhibition test using BHK-21 cells, micro culture plaque reduction test utilizing the LLC-
MK2 cell line, BHK-21 cells, a focus reduction method using peroxidase-antiperoxidase 
staining of BHK-21 cells, a screening test using a single dilution and a 70% plaque 
reduction endpoint and a simplified PRNT assay using BHK-21 cells. 
It is necessary to select the cell line capable of supporting plaque formation with 
each of four Dengue viruses, preferably LLC-MK2, Vero and BHK-2 cells. 
The PRNT involves incubating a constant number of plaque forming units (PFU). 
The standard protocol uses LLC-MK2 cells in six-well culture plates. Serial fourfold test 
serum dilutions, positive and negative serum controls are added to an equal volume of 
virus suspension diluted to contain 50 PFU‟s in the inoculum volume, placed in a shaker 
and incubated at 37‟C for one hour. The mixtures are then placed in an ice-bath, 
inoculated onto cells and allowed to absorb onto cells for one hour at room temperature. 
Then the first overlay medium containing an agar-nutrient mixture is added and incubated 
at 37˚C for 7 days, after which a second overlay containing neutral red is added, 
incubated at 35˚C overnight. Plaques are counted in each well on a fluorescent light box. 
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Use of higher percent plaque reduction endpoints will increase the specificity but 
decreases the sensitivity. No standards have been adopted for interpreting the assay. 
Earlier in the infection the neutralizing antibodies are of IgM type fairly specific to the 
infecting type. Later in the infection the antibodies are IgG.  
The limitations of this assay are its high cost, time consuming and technical 
difficulties
70
. 
MAC-ELISA: 
It is considered as a useful test for the diagnosis of Dengue. Serum, blood on filter 
paper, saliva and CSF (Dengue encephalitis) can be used for detection of IgM if samples 
are taken within the appropriate time (five days or more within the onset of fever). Serum 
specimens can be tested at a single or multiple dilutions. Most of the antigens used for 
this assay are derived from Dengue virus envelope protein. 
Total IgM is captured by anti µ chain specific antibodies coated on a micro plate. 
Dengue specific antigens (DENV 1 to 4 serotypes) are bound to the captured anti-Dengue 
IgM antibodies and are detected by monoclonal or polyclonal antibodies directly or 
indirectly conjugated with an enzyme that will transform a non-coloured substrate into 
coloured products. The optical density is measured by spectrophotometer (18). Results 
interpretation by using PANBIO IgM CAPTURE ELISA positive results >11panbio units 
(1.1 index), negative <9 panbiounits(0.9 index) and equivocal means 9-11 panbio 
units(0.9-1.1 index)
70
. 
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Figure 4 Principle of MAC-ELISA test.  Sensitivity of this test is much less than 
HI in acute phase samples, but the specificity is similar. It has been used for the 
surveillance of Dengue and DHF/DSS. It has the advantage of rapid diagnosis during 
epidemics and no inhibitor in patient‟s serum so no need of pre-treatment of test sera. The 
limitations of this test are cross reactivity with other flaviviruses
72,73
. 
IgG ELISA: 
It is useful for the detection of recent or past Dengue infection when paired sera 
are collected within the correct frame of time. The assay uses same antigens as in MAC-
ELISA
70
. Use of E/M specific capture IgG ELISA (GAC) helps in detection of IgG 
antibodies (peak at 6-15 days following infection)over a period of 10 months after the 
infection. It is used for the differentiation of primary and secondary infections and 
seroepidemiological studies. HAI titres> 1:2560 is Pnabio IgG cut off value is set to 
detect high levels of IgG antibodies above this threshold. It will not detect low level of 
IgG in many individual from endemic.so high level indicative of active secondary DENV 
infection. Results interpretation by using Panbio IgG Capture ELISA positive results 
>22panbio units (2.2 index), negative <18 panbiounits (1.8 index) and equivocal means 
18-22 panbio units (1.8-2.2 index). Early detection of elevated IgG levels in secondary 
infection can be possible from three days following infection, but high values are 
achieved when samples are obtained between 6 to 15 days after the onset of illness. 
Hence retesting of samples can be recommended between 4 to 7 days after the first 
specimen in cases of persistent infection. The limitations are lack of specificity, cross 
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reaction with other flaviviruses and not suitable for species identification.  (Panbio 
diagnostics). 
IgA ELISA: 
Dengue specific IgA has become target of interest in Dengue diagnosis. It appears 
earlier than IgM and IgG and also decreases rapidly. It is a better indicator of recent 
infection in serum and saliva ( non- invasive technique) with sensitivity of 94.4% and 
specificity of  74.7% in serum, slightly lower in saliva
74
. 
RAPID DIAGNOSTIC TEST (RDT NS1, IgM and IgG): 
This is only a screening test. Example, Dengue day 1 test, is a rapid solid phase 
immune-chromatographic test for qualitative detection of Dengue NS1 Ag and 
differential detection of IgM and IgG antibodies. 
PRINCIPLE: (ANTIGEN-ANTIBODY REACTION): 
  Dengue day 1 test kit for NS1 Ag has two lines, control and test lines. Test line is 
coated with anti-Dengue NS1 antigen. When a sample is added , Dengue NS1 Ag if 
present in the sample will bind to anti-Dengue NS1 gold colloid conjugate making 
antigen –antibody complex. This complex migrates along the membrane to the test region 
and forms the visible pink line (antibody-antigen-antibody gold conjugate complex). The 
sensitivity is 100% and specificity is 99.94%. 
Dengue IgM/IgG test device contains three lines, control line (C), IgM test line 
(M), and IgG test line (G). Test line of IgG and IgM is coated with anti-human IgG/IgM 
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monoclonal antibodies. When the sample is added to the well, IgG, IgM antibodies in the 
sample react with antihuman IgG or IgM antibodies coated on the membrane 
respectively. Colloidal gold with Dengue 1-4 antigen is captured by bound anti-Dengue 
IgG or IgM on respective test bands located in the test window causing a pale to dark red 
band. The sensitivity is 100% and specificity is 99.88%
75,76
. 
Other rapid tests are Inbios Dengue NS1 (sensitivity 86%, specificity 100%), 
Biorad NS1Ag strip (sensitivity 72.8%, specificity 100%), Panbio NS1 Ag strip 
(sensitivity 71.9%, specificity 95%)  and  SD Dengue dio (sensitivity 70.6%, specificity 
100%)
77
. 
HAEMATOLOGICAL TESTS: 
       Platelet and haematocrit (HCT) are measured during acute phases of infection. 
Platelet count < 100000 per  l is observed in DHF in the period between days 3 to 
8 following the onset of illness. HCT>20% is indicative of hypovolemia due to 
vascular permeability and vascular leakage. 
FUTURE TEST DEVELOPMENTS: 
MICROSPHERE – BASED IMMUNOASSAYS (MIAS): 
 It is based on covalent bonding of antigen or antibody to microspheres or beads. 
Detection method include laser to elicit fluorescence of varying wavelengths. It is faster 
than MAC-ELISA. The advantages of this test is its potential for multiplexing serological 
tests designed to identify antibody response to several viruses
67
. 
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MASS SPECTROMETRY: 
 It provides rapid discrimination of biological components in biological 
mixtures. It produces a specific finger print or molecular profile of virus. The software 
system built into the instrument identifies and quantifies the pathogen in a given sample. 
Additionally it recognize a previously unidentified organism, so it is useful in 
determining not only Dengue serotypes but also genotypes during an outbreak. Samples 
are processed for DNA extraction, PCR amplification, mass spectrometry and computer 
analysis
67
. 
MICROARRAY: 
It is possible to screen a sample for many different nucleic acid fragments 
corresponding to different viruses in parallel. Genetic material must be amplified before 
hybridization to the microarray, and amplification strategy can target conserved sequence 
as well as random based ones. Short oligonucleotides attached on microarray slide gives a 
relatively exact sequence identification. Laser based scanner is commonly used as a 
reader to detect amplified fragments labelled with fluorescent dye. It is used to test, at the 
same time, Dengue and other arboviruses responsible for Dengue like symptoms
67
. 
TREATMENT OF DENGUE INFECTION: 
The management of Dengue needs a stepwise approach as follows
67
 
 Step I- overall assessment- detailed history, physical examination, investigations 
including CBC and haematocrit for baseline assessment. 
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 Additional tests include LFT, RBS, urea and creatinine, serum electrolytes, 
bicarbonate/lactate, cardiac enzymes, ECG and urine specific gravity 
 Step II- lab diagnosis of Dengue, assessment of disease phase(febrile, 
critical/recovery) and severity by history, physical examination ,CBC, haematocrit, 
hydration ,haemodynamic status and warning signs present/not based on these 
parameters whether patient need admission /not 
 Step III- management- disease notification, management decisions. Based on the 
clinical manifestations patients may be categorized into three groups 
        Group A- patients can be sent home 
        Group B-patient may be referred for in-hospital management 
        Group C- require emergency treatment or urgent referral. 
TREATMENT OF GROUPS A TO C: 
GROUP A: 
These patients are able to tolerate oral rehydration and have good urine output 
without any warning signs. They should be monitored regularly and advised to return to 
hospital if they develop warning signs. Following protocol can be used. 
 Encourage plenty of oral fluids 
 For high grade fever give tepid sponging and paracetamol 6th hourly. Do not give 
NSAIDs as they aggravate gastritis or bleeding and may be associated with Reye‟s 
syndrome. 
 Advice hospital monitoring if patient develops any of the warning signs. 
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GROUP B: 
This group includes patients with warning signs, associated co morbidities and 
other social circumstances and they need in-hospital management. The following 
treatment protocol can be used. 
 Obtain haematocrit before fluid therapy. Give isotonic solutions such as 0.9% saline, 
Ringer‟s lactate or Hartmann‟s solution. Infusion should be titrated according to the 
clinical response. 
 Reassess the haematocrit and clinical status and increase or decrease the infusion 
accordingly. 
 Give minimum intravenous fluid volume required to maintain good perfusion and 
urine output of 0.5 ml/kg/hr. 
 Patients with warning signs should be monitored carefully for other organ functions. 
GROUP C: 
These patients have severe plasma leakage leading to shock, severe haemorrhage 
and severe organ impairment. They need emergency treatment and urgent referral. 
         Proper intravenous fluid resuscitation is essential. The crystalloid solution should 
be isotonic just sufficient to maintain the circulation. Larger volumes should not be 
infused as the patient may develop pulmonary edema. The primary aim of fluid 
resuscitation is to improve central and peripheral circulation and also improving end 
organ perfusion. 
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TREATMENT OF COMPENSATED SHOCK: 
Start IV isotonic crystalloid solution 5 to 10ml/kg/hr for one hour. Then asses the 
vitals, capillary refill time, haematocrit (HCT). If improved gradually reduce the infusion 
depending on the hemodynamic status which can be maintained for up to 24 to 48hours.  
If vital signs are unstable repeat second bolus 10 to 20 ml/kg/hr for one hour. Reduce the 
infusion rate if there is improvement in patient status. If haematocrit is <40% in children, 
females and <45% in adult males, it indicates bleeding and needs transfusion. 
TREATMENT OF HYPOTENSIVE SHOCK: 
Start IV fluid, isotonic crystalloid or colloid 20 ml/kg for 15 minutes. If improved 
maintain IV crystalloid or colloid 10 ml/kg /hr for one hour. Then maintain according to 
the haemodynamic status. If there is no improvement review first HCT value. If HCT is 
high administer second bolus IV colloid 10 to 20 ml/kg over one hour. If HCT is reduced 
consider bleeding and needs transfusion. If there is no improvement after the second 
bolus repeat second HCT and manage accordingly. Monitor HCT 6
th
 hourly. 
TREATMENT OF HAEMORRHAGIC COMPLICATIONS: 
Patients with profound thrombocytopenia advice strict bed rest, protect from 
trauma and no intramuscular injections. For severe thrombocytopenia prophylactic 
platelet transfusions should be given. 
  For severe bleeding give 5 to 10ml/kg of fresh packed red cells or 10 to 20ml/kg 
of fresh whole blood at an appropriate rate and observe the clinical response. A good 
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clinical response includes improving haemodynamic status and acid base balance. For 
further blood loss with reduced HCT transfuse platelet concentrates and FFP. 
TREATMENT OF COMPLICATIONS: 
FLUID OVERLOAD: 
Immediate oxygen therapy. Stop IV fluid. Oral or IV furosemide 0.1 to 0.5 
mg/kg/dose once or twice daily can be given. Monitor potassium and correct the ensuing 
hypokalaemia. If the still remains in shock careful fresh whole blood transfusion should 
be initiated. 
OTHER COMPLICATIONS: 
Both hypo and hyperglycaemia can occur. Electrolyte and acid base imbalances 
are also seen. Should be aware of coinfection and nosocomial infection. All these above 
mentioned abnormalities should be corrected. 
SUPPORTIVE CARE AND ADJUVANT THERAPY FOR SEVERE DENGUE: 
Instead of peritoneal dialysis prefer continuous veno-venous haemodialysis 
(CVVH) for renal replacement therapy. Vasopressors and ionotropic therapies are used to 
prevent life threatening hypotension, Dengue shock and during induction for intubation. 
Further treatment of organ impairment should be done. 
PREVENTION OF DENGUE INFECTION: 
Dengue virus transmission occurs when susceptible hosts, Dengue viruses, and 
mosquitoes capable of transmission are co-located in space and time. 
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ENDEMIC AREAS: 
Approaches for the prevention of Dengue infection and disease in endemic areas 
include Aedes mosquito control and vaccine development. 
MOSQUITO CONTROL: 
Mosquito control is effective but is difficult to sustain. Approaches to mosquito 
control for prevention of Dengue infection include: 
 Reducing breeding sites –by Community-based education to reduce breeding sites that 
accumulate standing water. 
 control of the aquatic stages( larvaland pupal) with temephos(OPC) and Bacillus 
thuringiensis israelensis (Biological agent) and water vessels can be seeded with 
copepods /guppy fish(Poecilla reticulate) that feed on mosquito larvae was successful. 
 Larva of Toxorhynchites are carnivorus.It is used for the control of Ae.Aegypti and 
Ae.albopictus larva. 
 Larva control Insecticide use- use of insecticide treated curtains-not much effective. 
 Endosymbiotic control-release of mosquitoes infected with intracellular 
endosymbiotic bacterium, Wolbachia can reduce the virustransmission. 
 Adulticiding by using Thermal fogs are produced by equipment which mixes an 
insecticide(pyrethroides) at a relatively low concentration with diesel oil or kerosene 
as a carrier
78
. 
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VACCINATION: 
Generally infection with one serotype provides long term protection with the same 
serotype and also some short lived protection against other serotypes. Ideal vaccine 
should provide protective immunity against all serotypes. One of the vaccine is CYD-
TDV (DENGVAXIA). It is a formulation of four chimeric yellow fever 17D Dengue 
vaccine viruses where the premembrane and envelope proteins from each Dengue virus 
types replaces the same proteins in a yellow fever 17D backbone virus. In one of the 
trails the vaccine was administered in three doses at months 0, 6, 12. Vaccine efficacy 
was significantly higher for DENV-3 and DENV-4 (approximately 75%) than DENV-1 
(50%) and DENV-2 (35-42%). The follow-up analyses of theses trails shows that the 
vaccine was associated with increased risk of Dengue infection requiring hospitalization 
during the third year of trail in children 2 to 5 years of age. Vaccine efficacy was also 
low
78
.  
Based on these data it was concluded that the vaccine may yield a public health 
benefit, though the durability of vaccine impact and level of herd immunity required to 
affect Dengue transmission are both unknown. According to WHO strategic advisory 
group of experts the vaccine should be introduced only in geographic settings with 
seroprevalence> 70% in the target age group. It should not be used if the seroprevalence 
is <50%. 
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TRAVELLERS: 
The primary preventive approach in travellers include, avoidance of exposure to 
infected mosquitoes such as remaining in a well screened or air conditioned area during 
day time. When outside during the day, they should wear protective clothing and use 
mosquito repellent such as N, N-diethyl-metatoluamide (DEET). 
Travellers from non-endemic countries are at low risk of severe Dengue infection 
in the absence of prior exposure. Exceptions are frequent international travel, military 
personnel and immigrants from endemic areas returning to their native place. 
People with history of Dengue infection need not avoid subsequent travel to 
endemic regions. Severe Dengue occurs in a small number of secondary infections, so the 
risk of severe infection is low in travellers
78
. 
FUTURE DIRECTIONS: 
So far there is no data to support the role of corticosteroids, intravenous 
immunoglobulins, pentoxifylline or activated factor VII. Some direct viral inhibitors are 
under trail. They are small molecule inhibitors of essential viral enzymes ( NS2B-3 
protease, NS3 helicase, NS5 methyltransferase, NS5 polymerase) or antibody inhibitors 
of viral entry/fusion. 
Randomized trails of chloroquine, lovastatin, balapiravir (polymerase inhibitor), 
celgosivir (alpha-glucosidase inhibitor) revealed no significant effects of these drugs or 
viremia, NS1 antigenemia or fever
78
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MATERIALS AND METHODS 
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This prospective observational study was conducted in the Department of 
Microbiology, PSGIMS&R after obtaining the Institutional Human Ethical Committee‟s 
approval. 
STUDY PERIOD: August 2016 to August 2017 
SAMPLE SIZE: 
Consecutive serum samples were collected from 150 hospitalized patients and 
outpatient with history of acute onset of fever less than 10 days duration, who were 
clinically suspected to have Dengue virus infection in and around Coimbatore.  
SAMPLE SIZE JUSTIFICATION: 
Formula used: n= t
2 
x p (1-p)/m
2 
Where; 
n = required sample size 
t = confidence level at 95% (standard value of 1.96) 
p = estimated prevalence of Dengue virus infection in and around Coimbatore 
m = margin of error at 5% (standard value of 0.05) 
Estimated prevalence from our hospital statistics (p) = 0.11 
n= 1.96 x 1.96 x 0.11 (1- 0.11)/ 0.05 x 0.05 
n= 153 (150) 
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INCLUSION CRITERIA: 
 As per the WHO classification, the proposed probable diagnosis were, 
1. An acute febrile illness with two or more of the following manifestations - headache, 
retro-orbital pain, arthralgia, rash, hemorrhagic manifestations, leucopenia and a 
positive IgM, antibody test on serum samples collected five or more days after the 
onset of fever supports the diagnosis of Dengue. 
2. A primary infection was indicated when the IgM to IgG index value ratio was 1.78  
3. A secondary infection was indicated when the IgM to IgG ratio was less than 1.78. 
4. Taking these criteria into account, patients have been categorized as suffering from 
primary/secondary infections 
EXCLUSION CRITERIA: 
1. Fever more than 10 days. 
 
ETHICAL CLEARANCE: 
This prospective study was approved by the Ethical Committee of PSG IMS&R. 
STATISTICAL ANALYSIS: 
Statistical analysis was performed using SPSS software (Statistical Product and 
Services Solutions, version 17, SPSS Inc, Chicago, Il, USA) to analysis data.  
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Figure 5: WORK FLOW CHART 
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SAMPLE COLLECTION: 
Blood samples were collected aseptically and serum was separated by 
centrifugation at 5000rpm/5min in room temperature.  Heat inactivated serum, 
Hemolysis, Icteric and Hyperlipemic process were not tried to avoid test erroneous 
results. 
Sodium azides as preservatives were not used because it inactivates HRPO 
enzyme. 
DENGUE NS1 Ag MICROLISA: 
It was an in-vitro qualitative detection of NS1 Ag from patients‟ serum/ plasma. It 
detects DENV1-4 serotypes. 
PRINCIPLE: 
It was based on direct sandwich ELISA. Polystyrene surface of micro wells coated 
with anti-Dengue NS1 antibodies with high reactivity for Dengue NS1 Ag. Samples were 
added to the wells followed by addition of Enzyme conjugate [monoclonal anti- Dengue 
NS1 antibodies linked to horseradish peroxidase (HRPO)].  NS1 was trapped/sandwiched 
between the antibody and antibody HRPO conjugate. Excess unbound conjugate was 
washed off with wash buffer. The amount of bound peroxidase was directly proportional 
to the concentration of Dengue NS1 Ag in the sample. Then add colourless TMB (Tetra 
methyl benzidine) and Chromogen, a blue colour developed by the cleavage of TMB with 
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HRPO enzymes.  The Enzyme-substrate reaction was limited by using Stop solution (1N 
H2SO4) and yellow colour develops which was read at 450nm spectrophotometrically. 
MATERIALS PROVIDED IN THE KIT: 
1. Anti NS1 antibody coated micro wells 
2. HRPO Conjugated anti NS1 monoclonal antibodies 
3. Diluent buffer containing protein stabilizers& antimicrobial agents as 
preservative 
4. Enzyme conjugate concentrate (50X) 
5. Wash buffer concentrate (25X)-concentrated phosphate buffer with surfactant. 
6. TMB substrate 
7. TMB diluent. 
8. Positive control-Recombinant Dengue NS1 antigen. 
9. Negative control-Normal human serum negative for Dengue NS1. 
10. Calibrator- Recombinant Dengue NS1 antigen. 
11. Stop solution. 
12. Plate sealers-Adhesive sheets to cover micro wells. 
MATERIALS NOT PROVIDED IN THE KIT: 
1. Micropipettes with disposable micro tips. 
2. Deionized water. 
3. Micro plate washing system. 
4. Micro plate reader with 450nm filter. 
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5. Timer 
6. Graduated cylinder 
7. Flask test tubes &plastic tubes or vials for dilutions 
8. Incubator 37˚C 
9. Disposable gloves  
10. Sodium hypochlorite solution 
PRE PROCEDURE PREPARATION: 
1. Working Wash Buffer: 1 ml of concentrated wash buffer＋24 ml of distilled water 
(1:25) 
2. Working Conjugate: 1 ml of conjugate concentrate＋49 ml of distilled water 
(1:50). 
3. Working Substrate Solution: 1ml of TMB＋1ml of TMB diluent (1:1). 
PROCEDURE: 
1. Required number of sample wells was taken along with 3 micro wells for 1 
positive control, 1 negative control and 1 for calibrator. 
2. The positive control, negative control, calibrator and serum samples were diluted 
with sample diluent by adding 50µl of controls/samples with 50µl sample diluent 
in each well. 
3. Added 100µl of working conjugate solution in each well and mixed well  
4. Incubated at 37˚C for 90 min. 
5. Then wells were washed with working wash buffer for 6 times. 
6. Add 150µl of working substrate solution in each well. 
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7. Incubated at 25˚C for 30 min in dark.  
8. Add 100µl stop solution. 
9. Read absorbance at 450nm with a reference filter of 600-650 nm within 30 min in 
ELISA Reader 
CALCULATION OF RESULTS: 
VALIDITY OF THE TEST: Negative O.D must be <0.3, Positive O.D >1.0, Mean 
calibrator O.D>/=0.35,Cut- off value >/=1.5 x NC O.D and Ratio of PC O.D/Cut off must 
be >1.1. 
a) Calculation of the triplicates of Calibrator „mean and multiply‟ by the calibration 
factor. Cut off value= mean O.D of calibrator x calibration factor. Calibration 
factor was batch specific. Value was 0.7 
b) An index value can be calculated by dividing the sample absorbance by the Cut- 
off value (calculated in step A).  Index value＝ Sample O.D/Cut-off value. 
c) NS1 Ag units can be calculated by multiplying the index valuex10 (as in step B) 
Table 4: Interpretation of results of Dengue NSI 
INDEX VALUE NS1 Ag  UNITS RESULTS 
＜0.9 ＜ 9 Negative 
0.9-1.1 9-11 Equivocal 
＞ 1.1 ＞  11 Positive 
        Sensitivity: 99.5%           Specificity: 100% 
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PANBIO DENGUE IgG CAPTURE ELISA: 
PRINCIPLE: 
Serum antibodies of the IgG class, when present, combines with anti- human IgG 
antibodies coated on micro well test strips.  A concentrated recombinant Dengue 1-4 
Antigens was diluted to correct working volume with antigen diluent.  An equal volume 
of HRPO - Conjugated monoclonal antibody (MAb) was added to the diluted antigen, 
allowing to form antigen- MAb complexes residual serum was removed by washing. This 
complex binds with serum Dengue specific IgG antibodies.  After incubation the micro 
wells were washed and a colourless substrate (TMB Chromogen) was added. The 
substrate was hydrolyzed by HRPO and the chromogen turns blue. Then stop solution 
was added, the TMB turns yellow. Colour development was indicative of presence of 
anti-Dengue IgG antibodies in patient‟s serum. 
MATERIALS PROVIDED IN THE KIT:                                        
1. Anti-human IgG-coated Micro wells 
2. Dengue 1-4 Recombinant Antigens  
3. Wash buffer-Phosphate buffer with Tween 20 and preservatives (0.1%proclin )                            
4. Sample Diluent-Tris buffer saline  
5. Antigen diluent-Phosphate buffer 
6. HRPO with MAb Tracer 
7. TMB Chromogen 
8. Dengue IgG Reactive control-human serum 
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9. Dengue IgG Capture Calibrator –human serum 
10. Dengue IgG capture Negative control-human serum 
11. Stop solution- 1M Phosphoric acid 
MATERIALS REQUIRED: 
1. Accurate adjustable micropipettes with disposable micro tips 
2. Deionized water 
3. Micro plate washing system. 
4. Micro plate reader with 450nm filter. 
5. Timer 
6. Graduated cylinder 
7. Flask test tubes & plastic tubes or vials for dilutions 
8. Incubator 37˚C 
9. Disposable gloves  
10. Sodium hypochlorite solution 
 
 PRE TEST PREPARATION: 
WORKING WASH BUFFER PREPARATION: 
Concentrated wash buffer 25 ml＋Distilled water 475ml (1:20 dilution) 
PROCEDURE 
1) Required number of sample wells were taken along with 3 wells for 1 positive 
control, 1 Negative control, 1 micro well for calibrator. 
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2) The PC, NC, Calibrator and Serum sample were diluted with sample diluent, by 
adding10µl of each with 1ml sample diluent in clean glass test tubes. 
3) Add 100 µl of this 1: 100 dilution samples and controls into respective wells.  If 
serum with IgG antibodies were attached to anti-human IgG antibodies coated in 
assay plate 
4) The plate was covered and incubated at 37˚C for one hour. After incubation, these 
wells were washed for 6 times by using wash buffer 
5) Dilute the Antigen 1/250 by using antigen diluents (10 µl of Ag with 2.5 ml of Ag 
diluent). 
6) Removed required amount of Ag and mix with an equal volume of MAb Tracer in 
separate vials.  Incubate at 20-25˚C for one hour 
7) Transfer 100µl of Ag-MAb per well to assay plate.  Cover plate and incubate 
1hour at 37˚C.Then wash the assay plate for 6 times 
8) Add 100 µl TMB in each well and incubate at 20-25˚C (dark) for10 minutes 
9) Then add 100 µl stop solution 
10) Read at 450 nm (Reference 600-650 nm). 
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CALCULATION OF RESULTS: 
VALIDITY OF THE TEST: Negative control O.D must be <0.400, Positive control/cut 
off ratio 1.1 – 7.0, Cut- off value >/=1.5 x NC O.D. 
a) Calculation of the triplicates of Calibrator mean and multiply by the calibration 
factor. Cut off value= mean O.D of calibrator x calibration factor. Calibration 
factor was batch specific. Value was 0.77 
b) An index value can be calculated by dividing the sample absorbance by the Cut- 
off value (calculated in step A).  Index value＝ Sample O.D/Cut-off value. 
c) Panbio units can be calculated by multiplying the index valuex10 (calculated in 
step B) 
Table 5: Interpretation of results of Dengue IgG 
     INDEX VALUE       PANBIO UNITS           RESULTS 
              ＜1.8                ＜ 18           Negative 
             1.8-2.2                18-22           Equivocal 
              ＞ 2.2               ＞  22           Positive 
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PANBIO DENGUE IgM CAPTURE ELISA: 
It was for the qualitative detection of IgM antibodies to Dengue antigen in serum. 
It could be detected 3to5 days after the onset fever and persists for 30 to90 days. 
Sometimes detectable levels may be present upto 8 months from the onset of fever. 
PRINCIPLE: 
Serum antibodies of the IgM class, when present, combine with anti- human IgM 
antibodies coated on micro well test strips. A concentrated recombinant Dengue 1-4 
Antigens was diluted to correct working volume with antigen diluent.  An equal volume 
of HRPO - Conjugated monoclonal antibody (MAb) was added to the diluted antigen, 
allowing to form antigen- MAb complexes.  Residual serum was removed by washing. 
This complex binds with serum Dengue specific IgM antibodies.  After incubation the 
micro wells washed and a colourless substrate (TMB Chromogen) was added. The 
substrate was hydrolyzed by HRPO and the chromogen turns blue. Then stop solution 
addition. The TMB turns yellow.  Colour development was indicative of presence of anti-
Dengue IgM antibodies in patient‟s serum. 
MATERIALS PROVIDED IN THE KIT: 
1. Anti-human IgM-coated Micro wells 
2. Dengue 1-4 Recombinant Antigens  
3. Wash buffer-Phosphate buffer(pH7.2-7.4) with Tween 20 and 
preservatives(0.1%proclin )                            
4. Sample Diluent-Tris buffer saline  
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5. Antigen diluent-Phosphate buffer 
6. HRPO with MAb Tracer 
7. TMB Chromogen 
8. Dengue IgM Reactive control-human serum 
9. Dengue IgM Capture Calibrator –human serum 
10. Dengue IgM capture Negative control-human serum 
11. Stop solution- 1M Phosphoric acid 
MATERIALS REQUIRED: 
1. Accurate adjustable micropipettes with disposable micro tips 
2. Deionized water 
3. Micro plate washing system. 
4. Micro plate reader with 450nm filter 
5. Timer 
6. Graduated cylinder 
7. Flask test tubes &plastic tubes or vials for dilutions 
8. Incubator 37˚C 
9. Disposable gloves  
10. Sodium hypochlorite solution 
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PRE TEST PREPARATION: 
WORKING WASH BUFFER PREPARATION: 
Concentrated wash buffer 25 ml ＋ Distilled water 475m l (1:20 dilution) 
PROCEDURE: 
1) Required number of sample wells was taken along with 3 wells for 1 positive 
control, 1 Negative control, 1 micro well for calibrator. 
2) The PC, NC, Calibrator and Serum sample were diluted with sample diluent, by 
adding 10µl of each with 1ml sample diluent in clean glass test tubes. 
3) Add 100µl of this 1: 100 dilution controls and samples into respective wells. 
Serum with IgM antibodies were attached to anti-human IgM antibodies coated in 
assay plate. 
4) The plate was covered and incubated at 37˚C for one hour. After incubation, these 
wells were washed for 6 times by using wash buffer. 
5) Dilute the Antigen 1/250 by using antigen diluents (10µl of Ag with 2.5ml of Ag 
diluent) 
6) Remove required amount of Ag and mix with an equal volume of MAb Tracer in 
separate vials .Incubate at 20-25˚C for one hour 
7) Transfer 100µl of Ag-MAb each wells to assay plate. Cover plate and incubate 
37˚C.  Then wash the assay plate for 6 times 
8) Add 100µl TMB in each well and incubate at 20-25˚C for10 minutes in dark 
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9) Then add 100µl stop solution 
10) Read at 450nm (Reference 600-650nm) 
CALCULATION OF RESULTS: 
Validity of the test: Negative O.D must be <0.400, Positive cut off ratio 1.1 – 8.0, Cut- 
off value >/=1.5 x NC O.D  
a) Calculation of the triplicates of Calibrator „mean and multiply‟ by the calibration 
factor. Cut off value= mean O.D of calibrator x calibration factor. Calibration 
factor was batch specific. Value was 0.96 
b) An index value can be calculated by dividing the sample absorbance by the Cut- 
off value (calculated in step A).  Index value＝ Sample O.D/Cut-off value 
c) Panbio 
 Units can be calculated by multiplying the index valuex10 (calculated in step B) 
Table 6: Interpretation of results Dengu IgM 
     INDEX VALUE       PANBIO UNITS           RESULTS 
              ＜0.9                ＜ 9           Negative 
             0.9-1.1                9-11           Equivocal 
              ＞ 1.1               ＞11           Positive 
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RNA EXTRACTION METHODS: 
To find out serotypes prevalence in this region various RNA extraction methods 
were tried to find out which was best method to isolate RNA, out of 150 continuous study 
samples 22 of NS1 Ag units was showed high value. These 22 samples were processed 
for molecular study. Finally I found out QIA symphony DSP virus / pathogen midi kit for 
RNA extraction was best method to isolate RNA from sample. 
 
QIASYMPHONY DSP VIRUS / PATHOGEN MIDI KIT 
 
PRINCIPLE: 
It comprises four steps including lyse, Bind, Wash & Elute.  This technology 
combines the speed and efficacy silica-based nucleic acid purification with the 
convenient handling of magnetic particles.  It was a safe and reproducible handling of 
potentially infectious samples by M/s QIAGEN GmbH, Germany. 
 
AIM: 
 
 Automated isolation and purification of nucleic acids from biological     specimens 
utilizing magnetic particle technology 
 Purification- high quality nucleic acid free of proteins, nucleases, and other 
impurities. 
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REAGENTS & MATERIALS PROVIDED  
 
RC-Reagent Cartridge has guanidine salts which form highly reactive compounds 
when combined with bleach. 
1- ER-Enzyme Rack 
2- PL-Piercing Lid 
3- AVE-Buffer AVE 
4- AVE- Buffer AVE 
5- CARRIER-Carrier RNA 
6- Proteinase K 
7- RSS-Reuse Seal Set 
 
MATERIALS REQUIRED: 
 
1- Sample prep Cartridge,8-well 
2- 8-Rod covers 
3- Filter-Tips,200µl and 1500µl 
4- Sample tubes 
5- Vortex 
For pathogen complex protocols 
Buffer ATL, internal controls, Sample tubes, 14ml 17x100 polystyrene, round –
bottom tubes from BD, Sample tubes 2 ml, with screw caps / without screw caps. 
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Figure 6: QIAsymphony RNA extraction method 
 
 
 
Figure 7: Dengue RNA extraction and purification 
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THINGS DONE BEFORE STARTING: 
Prepared all required mixtures, including mixtures containing carrier RNA 
(CARRIER) and internal controls (optional) just before starting. 
Make sure PL placed on RC and removal of lid of magnetic particles and open the 
enzyme tubes 
Barcodes if used for samples to be pasted and face in correct orientation. 
PROCEDURE: 
The QIAsymphony SP makes automated sample preparation which was easy and 
convenient.  
Kits were suitable for use with a wide range of sample types, including plasma, 
serum, CSF, and respiratory and urogenital samples.  Samples, reagents and 
consumables, and elutes were separated in different drawers.  Preparation of IC (Internal 
Controls) which contains carrier RNA 3µl, molecular biological grade water 14µl and 
buffer AVE 10µl per sample. 
Finally calculated the number of samples of the day run with addition of dead 
volume of three samples.  Then opened the sample drawer and placed the IC rack in the 
right end of A position.  Placed the tubes containing the carrier RNA-Buffer AVE 
mixture (including optional internal control) into slot A of the sample drawer and sample 
carrier in the sample slot.  Started the RUN button to start the purification process.  
Finally retrieved elution rack containing the purified nucleic acid from the eluate.  Then 
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store at 2~8˚C for short term storage upto 24hrs.  For long term storage, it will be -20˚C.  
Then close the instrument drawer and switch off machine.  
Simply load samples (1.5ml), reagents provided in special cartridges, and pre-
racked consumables in the appropriate drawer before run. Start the protocol and remove 
purified nucleic acids (60µL) from the “Eluate” drawer after processing. 
Figure 8: QIAsymphony reagent troughs 
 
LOW YIELD OF NUCLEIC ACID DUE TO, 
a) Magnetic particles were not completely re-suspended 
b) Frozen samples were not mixed properly after thawing 
c) Carrier RNA (CARRIER) not added 
d) Degraded nucleic acids 
e) Incomplete sample lysis 
f) Clogging of pipet tip due to insoluble material 
78 
 
From this test, only 14 samples had the ratio of OD260:OD280 more than 1.8 and 2.0 
respectively.  Hence all these 14 samples subjected to complementary DNA conversion 
and amplification. 
HIGH PURE RNA ISOLATION ROCHE KIT: 
PRINCIPLE: 
Serum /plasma lysed by binding buffer. Nucleic acid was bound to glass fibres 
pre-packed in the high pure filter tube.  Bound nucleic acid were washed with 
KIT CONTENT: 
1- Binding buffer-guanidine-HCL, Tris –HCL, Triton X 
2- Poly (A)-Carrier RNA for binding of RNA 
3- Inhibitor removal buffer-add with absolute ethanol, guanidine –HCL 
4-  Tris-HCL, p H-7.5 
5- Wash Buffer-add absolute ethanol, NaCL, Tris-HCL, p H-7.5 
6- Elution buffer-add PCR grade water 
7- High Pure Filter tubes- up to 700µl 
8- Absolute ethanol 
9- Micro centrifuge tubes 1.5 ml, sterile(Nuclease free) 
10-  Collection Tubes-2ml 
11-  Sample material-200 to 600 µl of serum, plasma, urine, or cell culture supernatant 
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PROCEDURE: 
Add 200μl of serum in 400μl PBS (phosphate buffer solution) with Poly (A). 
Vortex it for 1 minute then to transfer the sample to a High Pure Filter Tube which was 
inserted into one collection tube.   Pipet the entire sample into the upper reservoir of the 
Filter Tube (max 700μl).  Insert the entire High Pure Filter Tube assembly into a 
Standard table-top centrifuge. Centrifuge the tube assembly at 8000rpm/1min. After 
centrifugation, remove the Filter Tube from the Collection tube.  Discard the flow 
through, and again combine the Filter tube and the used Collection tube. After re-
inserting the Filter Tube, then add 500μl of inhibitor removal buffer to the upper 
reservoir. Centrifuge the tube assembly at 8000rpm/1min.  
Pipet the 450μl Wash Buffer to the upper reservoir of the filter Tube assembly and 
centrifuge 8,000 rpm/1min.  Discard the flow through and combine the Filter Tube with 
the used Collection Tube.  Again 450μl Wash Buffer to the upper reservoir of the filter 
Tube assembly and centrifuge 8,000 rpm/1min. Discard the flow through and combine 
the Filter Tube with the sterile Collection Tube. To elute the RNA, Add 50μl Elution 
Buffer to the upper reservoir of the Filter Tube. Centrifuge the tube assembly at 
13,000rpm /1m.  Filter Tube assembly and centrifuged for another 1 min at 13,000rpm to 
remove any residual Wash Buffer.  The micro centrifuge tube contains the eluted, 
purified RNA, which can be used directly in RT-PCR or stored at –80°C for later 
analysis.  
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RNA EXTRACTION BY USING QIAGEN KIT: 
EXTRACTION STEPS: 
Added 560µl of prepared buffer AVL to a clean 1.5 ml tube with 5.6µl of carrier 
RNA to this addition of 140µl of sample to the same tube which was incubated at room 
temperature for 10 min.  In this 560µl of ethanol was added and mixed by vortex.  From 
this transferred 630 µl of Lysate into upper reservoir of spin column. Closed it and 
centrifuged at 8000rpm/ 1min.transfer spin column tube to a new 2ml collection tube. 
Add 500µl of AW1 and centrifuge at 8000rpm/1min.Then spin column tube was 
transferred to a new 2ml collection tube.  Then added 500µl of AW2 and centrifuge at 
14,000rpm/4min and transfering spin column tube to a new 1.5 ml tube for elution. 
Added 60µl of elution buffer and kept it for 5min at room temperature, centrifuge it 
10,000rpm /1min.  Finally eluted RNA was collected in 1.5 ml tube and discard the spin 
column tube. This eluted Genomic RNA was directly used for RNA agarose 
formaldehyde gel run and remaining RNA elute was stored at -20˚C for further 
conversion of cDNA. 
SPECTROPHOTOMETRY OF RNA: 
It was rapid, simple and non-destructive absorption Spectroscopy has been the 
method of choice to measure the amount of RNA and DNA in the concentrated pure 
solution by taking reading at 260nm.  For quantitating the amount of RNA, readings were 
taken at Wave Length (WL) of 260nm and 280nm.  The concentration of nucleic acid 
(NA) in the sample was calculated by readings taken at 260nm.  An OD of 1 corresponds 
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to ~50µg/ml for ds DNA, 40µg/ml for RNA.  The Ratio between readings at 260nm and 
280nm (OD260:OD280) provides the purity of the NA.  The values of 1.8 and 2.0 
respectively.  If there was a contamination of protein or phenol, OD260:OD280 will be less 
than the above value. 
By using this method, quantification of RNA done for 150 samples progressively 
special inhibitor removal buffer to get rid of RT-PCR inhibitory contaminants. It allows 
even the application of heparinized sample material with >100u/ml heparin. Washing of 
bound nucleic, purification from salts, protein and other cellular impurities. Purified 
nucleic acids were recovered using the elution 
 MOBS BUFFER GEL ELECTROPHORESESIS USING FORMALDEHYDE: 
By using this method, quality of the isolated RNA will be checked.  Pathogenic 
RNA Vs Micro RNA in the samples were identified.  Micro RNA show less than 100 bp 
size while pathogenic RNA exhibits more than 100bp size. 
ORION X ONE STEP RT-PCR SMART MIX (2X): 
RT-PCR was done for 14 isolates which had OD ratio of OD260:OD280 more 
than 1.8 and 2.0 respectively.  OrionX  One Step RT-PCR smart mix was a product for 
easy reverse transcription and PCR at “One Step” with optimal recombinant of Reverse 
Transcriptase and HotStart h-Taq DNA polymerase mixture.  This kit has dual advantage 
of high efficacy for cDNA synthesis and high specificity of hot start polymerase to setup 
82 
 
of optimal PCR conditions easily and conveniently from M/s Origin Diagnostics, 
Thiruvananthapuram, Kerala. The kit can be stored at -20°C. 
PRINCIPLE: 
Extracted Dengue viral RNA from the serum samples was converted to cDNA by 
using reverse primer D2 and reverse transcriptase enzymes.  Within a single tube, cDNA 
was amplified by using universal Dengue viral D1&D2 primers.  Identification of the 
four serotypes was achieved by nested amplification of a primary product generated with 
D1&D2. 
The expected size of the RT-PCR products was 511 bp by using universal Dengue 
viral primers D1&D2.  Expected size of each amplicons for the each Dengue serotypes 
were TS1 – 482 bp, TS2 – 119 bp, TS3 - 290 bp and TS4 – 392 bp. The primers were 
diluted 1:10 with molecular grade water before use. The remaining volume was adjusted 
with PCR grade water. 
Table 7: Dengue Primers used in this study were: 
Gene Primer sequence (5’-3’) Amplicon size (bp) Reference 
D1 5'-TCAATATGCTGAAACGCGCGAGAAACCG-3' 511  
D2 5'-TTGCACCAACAGTCAATGTCTTCAGGTTC-3' 511  
TS1 5'-CGTCTCAGTGATCCGGGGG-3' 482 (D1 & TS1)  
TS2 5'-CGCCACAAGGGCCATGAACAG-3' 119 (D1 & TS2)  
TS3 5'-TAACATCATCATGAGACAGAGC-3' 290 (D1 & TS3)  
TS4 5'-CTCTGTTGTCTTAAACAAGAGA-3' 392 (D1 & TS4)  
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FEATURES OF ONE STEP KIT: 
RTase M-MLV RTase (RNase H
-
) 
Temperature of cDNA synthesis 42-55 ˚C 
Synthesis length <1 kb 
Synthesis primer Gene specific primer 
Expiration date 1 year 
Other materials required: 
- Cell free samples (such as Plasma or serum samples) 
- Vortex mixer 
- Cold (4˚C)Micro centrifuge 
- 0.5 ml Eppendorf tubes 
- Micropipettes (100-1000μL, 10-100μL, 1-10μL) 
- Sterilized Microtips (100-1000μL, 10-100μL, 1-10μL) 
- Molecular grade water 
- The eluted cDNA amplified product  was stored in 0.5ml Eppendorf tubes at -
20°C. 
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PROCEDURE: 
The Single step Nested RT- PCR was performed by using cDNA production  in 
the conventional method using Applied Bio systems Step One Real-time PCR system 
immediately after the extraction  purified viral RNA. 
After preparation of PCR mixture with total volume of 30µl as mentioned below 
the table, the PCR cycle was initiated with initial holding temperature 50˚C for 30 
minutes in single cycle for conversion of cDNA followed by denaturation was done at 
95°C for 15 minutes in a single cycle followed by 95°C for 20 seconds followed by 
annealing temperature 55°C for 45 seconds in 40 cycles and followed by extension at 
72°C for 60 seconds and a final elongation at 72°C for 5 minutes. Identification of the 
four serotypes was achieved by Single step nested amplification of a primary product 
generated with D1&D2.Below table shows the recommended PCR mixture and cycling: 
Table 8: Orion X -one step PCR mixtures and cycle for Dengue Serotyping 
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The amplified products were stored at -20°C until they were subjected to gel 
electrophoresis. 
DETECTION OF PCR PRODUCTS BY AGAROSE GEL ELECTROPHORESIS: 
The amplified products were visualized by agarose gel electrophoresis. 2% 
agarose gel was prepared by adding nuclease and protease free agarose powder with 1x 
Tris Borate EDTA (TBE) buffer. This mixture was heated in the microwave until it 
formed a clear solution and 0.2μL of ethidium bromide was added to visualise the 
amplified DNA under UV light. The mixture was allowed to set in an electrophoresis 
tank with a comb in place. 
5µl of a 100 base pair DNA ladder was used as the molecular marker to measure 
the size of the amplified product and was added in the first well. The rest of the wells had 
25μL of the amplified product with loading dye 3μL per sample. Gel electrophoresis was 
performed by placing the gel in an electrophoresis tank containing 1x TBE buffer at 70 
volts for 2 hour. 
INTERPRETATION: 
Following electrophoresis, images of the gel were captured by Gel Doc.  By 
comparing with the 100 base pair ladder, the size of the amplified product was measured 
and noted down. 
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RESULTS 
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The total number of patients with suspected Dengue in our hospital from August 
2016 to August 2017 was 6557. All samples were tested for Dengue IgM and IgG 
antibodies by using Dengue IgM and IgG capture ELISA and /orNS1 Antigen depending 
on the duration of fever. NS1 was tested in cases with fever of less than five days 
duration. With these parameters the total seropositivity was 70.81 % (4643).  
 
Figure 9: Total seropositive Dengue cases recorded during study Period 
                  
 
 
 
6557 
4643 
Total Case Seropositive Cases
Total vs. Seropositive Case 
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Figure 10: Male to female sex distribution in Dengue 
 
It was observed that no significant difference in male to female sex ratio. Only 
slight increase in male patients was seen. 
Figure 11: Age dependent distribution of Dengue cases 
 
The above data shows that patients in the age group between 11 to 19 years were 
commonly affected.  
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            Figure 12: Month wise distribution of Dengue seropositive cases 
 
 
It was observed from the above data that more number of cases was seen during 
the months of July and August. 
RESULTS OF NS1 ANTIGEN MICROLISA: 
Consecutive 150 serum samples were collected from patients who had <  9 days of 
fever and subjected to NS1 antigen detection. NS1 antigen detection was done by using 
Microlisa. Clinical data was collected from NS1 antigen positive patients and parameters 
like sex distribution, platelet counts, liver enzymes, WBC counts, packed cell volume and 
duration of fever were assessed. 
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 Table 9: Primary Dengue infection with WHO clinical classification  
Serological 
test 
Dengue 
without 
Warning signs 
Dengue with 
warning signs 
Severe 
Dengue 
Total 
NS1 Only
 31 (63.26%) 10 (76.92) 3 (75%) 44 
NS1+IgM 8 (16.33%) 2(15.38 %) 1 (25%) 11 
IgM Only 10 (20.41%) 1 (7.70 %) - 11 
Total 49 13 4 66 
 
Table 9 shows NS1 only positivity was high when compared to other parameters. 
In Dengue without warning signs NS1 Positivity was 63.26%(31), with warning signs 
76.92%(10) and 75%(3) of severe Dengue. 
 
Table 10: Secondary Dengue infection with WHO clinical classification 
Serological 
test 
Dengue 
without 
Warning signs 
Dengue with 
warning signs 
Severe 
Dengue 
Total 
NS1+IgM+IgG
 6 (17.65%) 4 (25%) 1 (50%) 11 
IgM+IgG 27 (79.41%) 12(75 %) 1 (50%) 40 
IgG Only 1(2.91%) - - 1 
 
NS1+IgG - - - 0 
Total 34 16 2 52 
 
Table 10 shows high IgM+IgG positivity in secondary Dengue when compared to 
other parameters irrespective of the clinical severity. IgM+IgG positivity in Dengue 
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without warning signs is 79.41 % (27), with warning signs is 75 % (12) and 50 % (1) in 
severe Dengue. 
 Table 11: Distribution of platelet counts in primary Dengue  
Platelet 
count 
Dengue 
without 
warning 
sign 
Dengue 
with 
warning 
sign 
Severe 
Dengue 
<150x 10 
3
 30 (61.22) 10 (83.33) 4 (100%) 
150-400 x 
10
3
 
18 (36.73) 1 (8.33) 0 
>400 x 10
3
 1( 2.05) 1 (8.33) 0 
 
Among the study population, 61.22 % (30) cases of Dengue without warning 
signs, 83.33 % (10) cases of Dengue with warning signs and 100 % (4) of severe Dengue 
had thrombocytopenia. 
 
Table 12: Distribution of platelet counts in secondary Dengue  
Platelet 
count 
Dengue 
without 
warning 
sign 
Dengue 
with 
warning 
sign 
Severe 
Dengue 
<150x 10 
3
 30 (88.23) 15 (93.75) 2 (100%) 
150-400 x 
10
3
 
3 (8.82) 1 (6.25) 0 
>400 x 10
3
 1( 2.95) 0 0 
 
Among the study population 88.23 % (30) cases of Dengue without warning signs, 
93.75 % (15) cases of Dengue with warning signs and 100 % (2) of severe Dengue had 
thrombocytopenia. Hence thrombocytopenia was seen in majority of Dengue cases, serial 
monitoring of platelet count is mandatory.   
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Table 13: Packed cell volume (PCV) in primary Dengue infection  
PCV Dengue 
without  
Warning sign 
Dengue with 
warning sign 
Severe 
Dengue 
Total 
< 35 % 8 (16.33%) 4 (30.77 %) 1 (25 %) 13 
35-45 % 33 (67.35 %) 7 (53.85 %) 1 (25 %) 41 
>45 % 8 (16.32 %) 2 (15.38 %) 2 (50%) 12 
 49 13 4 66 
 
Table 13 shows that 50 % (2) cases of severe Dengue had elevated packed cell 
volume in primary Dengue. 
 
Table 14: Packed cell volume  (PCV) in Secondary Dengue infection 
PCV Dengue 
without  
Warning sign 
Dengue with 
warning sign 
Severe 
Dengue 
Total 
< 35 % 4 (11.76%) 3 (18.75 %) 0  7 
35-45 % 25 (73.53 %) 12 (75 %) 0  37 
>45 % 5 (14.71 %) 1 (6.25 %) 2 (100%) 8 
 34 16 2 52 
 
Table 14 shows that 100 %(2) cases of severe Dengue had elevated packed cell 
volume in secondary Dengue. Normal PCV is in the range of 40-45 % for men and 35-40 
% for women. Hence significantly elevated PCV were seen in severe Dengue, more in 
cases of secondary Dengue 
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Table 15: White blood cell (WBC) count in Dengue Primary and secondary 
infections 
WBC 
count/ µL 
Primary Secondary 
Dengue 
without 
warning signs 
Dengue 
with 
warning 
signs 
Severe 
Dengue  
Dengue 
without 
warning 
signs 
Dengue 
with 
warning 
signs 
Severe 
Dengue  
< 4000 16 32.65%) 1 (7.69%) 1 (25%) 13 (38.23%) 0 1 (50%) 
>4000 - 11, 
000 
30 (61.23%) 10 (76.92%) 3 (75%) 20 (58.82%) 15 (93.75%) 1 (50%) 
>11000 3 (6.12%) 2 (15.38%) 0 1 (2.94%) 1 (6.25%) 0 
 49 13 4 34 16 2 
 
Table 15 shows that there was no significant leukocytosis or leukopenia in 
primary/ secondary Dengue, irrespective of the clinical severity. 
 
Table 16: Duration of fever in Dengue infection 
Fever 
duration 
(in days) 
Dengue without warning 
signs 
Dengue with warning 
signs 
Severe Dengue  
Primary  Secondary Primary  Secondary Primary  Secondary 
≤ 4 days 41 (83.67%) 21 (61.76%) 5 (38.46%)  6 (37.50%) 0 0 
> 4 days 8 (16.33%) 13 (38.24%) 8 (61.54%)  10 (62.50%) 4 (100%) 2 (100%) 
 49 34 13 16 4 2 
 
Table 16 shows that patients with severe Dengue and Dengue with warning signs 
had more than 4 days of fever in primary and secondary Dengue, indirectly indicating 
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viremia. Persistent viremia was associated with severity of diseases. Patients without 
warning signs had less than 4 days of fever in primary and secondary Dengue.  
 
      Table 17: Association between serological classification of Dengue and Sex 
Serological test Male  Female Pearson Chi-
square Value 
‘P’ Value 
Dengue Negative 11 (14.4%) 21 (27.6 %) 
3.649 
0.161 
(NS) 
Primary Dengue 
infection 
35 (47.3%) 31 (40.8 %) 
 
 
Secondary 
Dengue infection 
28 (38.1) 24 (31.6%) 
 
 
 
Table 17 shows that there was no significant difference in male to female ratio in 
primary, secondary and serological negative Dengue cases (P value: 0.161). 
 
Table 18: Association between serological classification and liver enzyme level 
Serological  
classification  
Liver 
enzyme not 
done 
Liver 
enzyme 
normal 
Liver 
enzyme  
elevated 
Pearson 
Chi-square 
Value 
‘P’ Value 
Negative 14 (82.4%) 11 (15.1%) 7 (11.7 %) 
51.42 
0.00 
(S) 
Primary 
Dengue  
3 (17.6%) 41 (56.2%) 22 (36.7%) 
Secondary 
Dengue  
0 21 (40.4%) 31 (51.6 %) 
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Table 18 shows a strong association between elevated liver enzymes and 
serological classification, more in secondary Dengue 59.6 % (31 cases) when compared 
to primary Dengue 36.7 % (22 cases) (P value: 0.00). 
Table 19: Association between platelet counts and WHO classification of Dengue 
Serological 
Classification 
Platelet 
Count 
< 150X10
3 
Platelet 
Count 
150-400 X 
10
3
 
Platelet 
Count 
> 400 X10
3
 
Total Pearson 
chi-
square 
value 
P 
value 
Negative 8 (25%) 23 (71.9 % 1 (3.1%) 32 
44.100 0.00 (S) 
Primary 
Dengue  
46 (69.7%) 19 (28.8 %) 1 (1.5 %) 66 
Secondary 
Dengue  
47 (90.4%) 4 (7.7 %) 1 (1.9 %) 52 
 
Table 19 shows that there was a strong association between thrombocytopenia and 
clinical severity of the infection. (P value: 0.00).  Thrombocytopenia was seen in 90.4 % 
(47 cases) of secondary Dengue, 69.7 % (46 cases) of primary Dengue and even seen in 
25 % (8 cases) of sero-negative patients. 
ISOLATION OF DENGUE RNA: 
Dengue viral RNA was extracted by 1. QIA symphony DSP virus/pathogen midi 
kit,2. QIA symphony DSP virus/pathogen mini kit ,3. Roche kit and 4.QIAGEN kit, of 
which the midi kit was the best method which is shown in figure 14.  
RNA PURITY AND CONCENTRATION CHECK: 
Isolated RNA was subjected to spectrophotometry at wavelengths of 260 and 
280(A260, A280). Twenty two samples with more than 50 NS1 antigen units were subjected 
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to RNA extraction by QIAsymphony midi kit which showed  more than 40 microgram 
per milliliter of RNA, which was subjected to PCR. 
ONE STEP MULTIPLEX-NESTED RT-PCR: 
Out of 22 samples subjected to one step multiplex Nested RT-  PCR, 15 samples 
showed Dengue amplicons with base pair 119(serotype2), base pair 290(serotype3) and 
base pair 119&290(serotype 2&3) as shown in figures 16,17,18 respectively. 
Table 20:  Distribution of Dengue serotypes in study group 
Base pair size Serotypes  Total positivity Percentage (%) 
119 DENV-2 4 18.18 
290 DENV-3 5 22.73 
119&290 DENV-2&3 6 27.27 
 
Figure 13: Distribution of Dengue p
 
7 
4 5 
6 
Negative DENV-2 DENV-3 DENV-2&3
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Table 20 shows that the most common serotype identified was DENV-2 and 
DENV-3 co-infection 27.27%(6) followed by DENV-3 22.73%(5) and DENV-2 
18.18%(4). 
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Figure 14: Electrophoresis of Extracted RNA by various methods 
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Figure 15: MOBS buffer Gel Electrophoresis using formaldehyde for 
Purification of extracted RNA identification 
Lane-1 DNA Marker (100bp) 
Lane-3 showed Dengue Viral RNA. 
Lane – 1&3 showed mRNA 
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Figure 16: Result of Gel Electrophoresis of Dengue Serotype-2 
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Figure 17: Results of Gel Electrophoresis of Dengue Serotype-3 
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Figure 18: Results of Gel Electrophoresis of Dengue Serotype-2&3 
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Figure 19: QIAGEN RNA Extraction (Automatic) 
 
 
 
 
 
 
 
 
Figure 20: Spectrophotometer to deduct RNA Concentration 
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Figure 21: ABI Step-1 Real-time PCR Thermo Cycler 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thermocycler- PCR cycle 
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DISCUSSION 
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Dengue is one of the major mosquito borne viral disease with rapid rise in 
incidence in the last 50 years. Dengue infects an estimated 50 to 100 million people and 
responsible for increase in hospitalization and deaths. Since more than half of the infected 
individuals presents as asymptomatic or mild undifferentiated fever, the diagnosis is 
primarily based on the combination of clinical features, serology and molecular testing. 
According to National Vector Borne disease Control Programme-(Delhi) statistics as on 
8th October 2017 the total Dengue positive cases  all over India were 78691 out of which 
number death were 122and in Tamilnadu total cases were 11552 out of which number of 
death were 18. 
Dengue infection may be primary or secondary. Primary infection can be 
subclinical or manifests as minor symptoms in most of the affected individuals. 
Secondary infection is more commonly associated with severe disease manifestations like 
Dengue haemorrhagic fever or Dengue shock syndrome. In primary Dengue infection the 
earliest antibody response is IgM appearing by third day, followed by IgG in later phase 
(6 to 15 days) of the disease persisting for more than six months following infection. In 
secondary Dengue infection, IgG antibodies will be detected even during the early acute 
phase, whereas IgM will be low or absent. Hence the presence of IgM antibodies in 
earlier phase of the disease indicates primary infection and presence of IgG indicates 
secondary infection. 
Viral non-structural antigen (NS1) is abundant in the serum during earlier stages 
of infection; therefore NS1 antigen ELISA along with IgM capture ELISA will be more 
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effective during an endemic setting. In a study conducted by King institute, Chennai
82
 
during 2006 to 2008 showed 43% Dengue seropositivity with 16.47% being secondary 
infections. Another study conducted in Bangalore by Atul Garg et al
83
 between 2006 to 
2010 showed maximum seropositivity during 2010 (46.5%) and 92% were secondary 
infections. In our study the seropositivity over the years was 78.67% with 55.9% primary 
Dengue and44.1%secondary Dengue. But during the study period of one year, secondary 
Dengue found to be common than primary. 
Generally there is no significant difference in male to female ratio of Dengue 
infection
43
. In a study conducted by Vemu Lakshmi et al
65
, the male to female ratio was 
2:1 during 2007. Another study by Tina Damodar et al
84
 in Mangalore showed that male 
to female ratio was 2:1. In our study, male to female ratio was 1.2:1.As Dengue 
prevalence increases all part of our country over the years the ratio of affecting male and 
female are equal. 
Commonly affected age group in our study was 11to 20 years (32%), followed by 
21 to 30 years (18.7%) with mean age of 26 years.Arti Sharma et al from Madhya Pradesh 
showed 11 -20 was most common followed by21-30 years. Study by Meena Dias and Tina 
Damodar et al
84
. the most commonly affected age group was between 21 to 40 years (54%), 
followed by 10 to 20 years (19%). M. Neeraja et al
85
 showed that the most commonly 
affected age group was between 20 to 39 years. 
Numbers of Dengue cases are more during the monsoon and post monsoon season. 
Tamilnadu receives maximum rainfall from North East monsoon during October to 
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November .during the south west monsoon (SWN) from June to September Coimbatore 
district receives  32% of total annual rainfall of Tamilnadu.In our study, maximum 
number of cases were seen between the months of July (23.4%) and August (19.5%). In a 
laboratory based Dengue surveillance study conducted by John Victor et al
86
 in 2007, the 
data on month wise incidence of Dengue in Tamilnadu for the past nine years revealed 
that the number of cases increased from June to December.  PM Ukey et al
87
observed 
maximum Dengue cases in central part of India during September to November.  
We observed IgM in 22.45%, IgM&IgG in 26.20% and IgG in 22.16%, indicating 
predominance of secondary Dengue infection than primary. Similar observations were 
made in another study from south India with 18% IgM positivity, 32% IgG positivity and 
50% IgM and IgG positivity.  
The Dengue virus NS1 antigen was found to be circulating in the sera of patients 
during the acute phase of illness from day 1 to day 9
43
. It has both group specific and type 
specific determinants. The NS1 antigen capture ELISA has been shown to be useful in 
determining Dengue infection in acute phase sera during both primary and secondary 
infections, although the sensitivity of detection is higher in primary infections. A possible 
explanation for reduced NS1 antigen sensitivity during secondary Dengue is due to the 
presence of anti-DENV antibody, plasma NS1 antigen sequestrated in immune 
complexes and the target epitopes are not accessible for its detection
43
.In a study by 
Damodar T et al
84
. NS1 antigen was detected in 49% of patients with less than 5 days of 
fever. Another study by S Datta and Wattal
8
 found that 71.42% NS1 antigen positivity 
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when samples were collected within 5 days of fever. In our study of selected 150 
consecutive patients NS1 antigen positivity was 55.93 %(66). NS1 antigen is detected in 
68.2% of patients with less than 5 days of fever and in 31.8% patients with more than 5 
days of fever. 
Normal platelet count is 150 to 400x10
3. 
In majority of Dengue patients 
thrombocytopenia is transient and asymptomatic. But in significant number of cases there 
are bleeding manifestations. Thrombocytopenia is due to immune mediated platelet 
destruction. When platelet counts are in the range of 20 to 40 thousands, 
petechiae/purpura is seen and when counts are less than 20 thousands, spontaneous 
bleeding is seen. 
 
Most commonly observed significant laboratory parameter in Dengue is 
thrombocytopenia which we observed in 69.7% of primary Dengue and 90.45% of 
secondary Dengue. 
Normal PCV is in the range of 40-45 % for men and 35-40 % for women. 
Significantly elevated PCV were seen in severe Dengue, more in cases of secondary 
Dengue infection in our study (100%). Plasma leakage is evidenced by increase in 
hematocrit equal to or more than 20% above average for age, sex and population or signs 
of plasma leakage such as pleural effusion, ascites and hypoproteinemia. 
Liver enzymes such as aspartate aminotransferase and alanine aminotransferase 
are commonly elevated in Dengue infections. Other enzymes like alkaline phosphatase 
and gamma glutamyl transpeptidase are also elevated in minority of patients
83
.Significant 
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elevated liver enzymes were found in 36.7% of primary infection and in 51.6%secondary 
Dengue. Similar observation was made in studies by Damodar T et al
84
. 
Molecular techniques allows for multi-fold biological amplification of viral RNA 
and has been used for rapid diagnosis of viral diseases. The main advantage is faster 
screening, high sensitivity and specificity and can detect even small quantities of virus. 
This method is also used to detect the Dengue virus serotyping both in clinical samples 
and in Aedes mosquitoes. RT-PCR is the gold standard test one of the important steps in 
the molecular diagnosis of Dengue virus
80
.  
Extraction is an important prerequisite for a successful molecular detection of any 
viral pathogen.We used four methods for RNA extraction. They were 1). QIA symphony 
DSP virus/pathogen midi kit for RNA extraction, 2). QIA symphony DSP virus/pathogen 
mini kit for RNA extraction, 3). Roche kit and 4).QIAGEN kit. 
Out of which QIA symphony DSP virus/pathogen midi kit yielded higher 
concentrations of RNA than the other methods. Further purification of RNA was 
achieved by spectrophotometry. All samples showed more than 40µg/ml of RNA. 
Extracted RNA was subjected to MOBS buffer Electrophoresis using formaldehyde gel  
to detect and differentiate Dengue RNA from non-specific microRNA normally present 
in serum. 
Dengue viral RNA was amplified by various methods. They were Reverse 
transcriptase PCR(RT-PCR),Real time PCR(qRT-PCR), Transcription mediated 
amplification(TMA), Nucleic acid sequence based amplification(NASBA) and loop 
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mediated isothermal amplification(LAMP).In RT-PCR CprM(Core pre-Membrane) 
structural region was amplified for identification of Dengue virus. We used single step 
multiplex nested RT-PCR, using the primers designed by Lanciotti et al
66
. The primers 
used were as follows 
D1-5'-TCAATATGCTGAAACGCGCGAGAAACCG-3'-511 
D2-5'-TTGCACCAACAGTCAATGTCTTCAGGTTC-3'-511  
TS1-5'-CGTCTCAGTGATCCGGGGG-3'-482 (D1 & TS1),  
TS2-5'-CGCC ACAAGGGCCATGAACAG-3'-119 (D1 & TS2),  
TS3-5'-TAACATCATCATGAGACAGAGC-3'-290(D1&TS3) 
TS4-5'-CTCTGTTGTCTTAAACAAGAGA-3'-392 (D1 & TS4) 
 
The advantages of this test is its better sensitivity and accurate detection of viral 
RNA for a specific serotype. The main disadvantage is its cost and requires expertise. We 
could not use real time PCR as it is very expensive. 
There are five serotypes of Dengue virus, DENV 1 to 5, fifth being the latest 
addition. The fifth and the latest serotype have been declared in October 2013. This 
serotype was found in the sample of a 37 year old farmer from Sarawak state of Malaysia 
in 2007
79
. Most of the infections are due to serotypes 1 to 4 with increase in incidence of 
cross infection among the serotypes. Increase in cross infection leads to the emergence of 
recombinant strains and disease severity.  
Among the serotypes of Dengue virus, Asian serotypes of DENV-2&3 are 
frequently associated with secondary Dengue infection as observed by Tina Damodar et 
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al
84
. Neeraj et al showed that the common serotype was DENV-3 followed by DENV-4 
in southern part of India. In our study DENV-3 was the most common followed by 
DENV-2. However DENV-2 and DENV-3 coinfection was seen in 27.27% of cases 
followed by DENV-3 in 22.73% and DENV-2-18.88%. 
Fifty percent of coinfection with DENV-2 and DENV-3 in our study were 
associated with increase in disease severity leading to Dengue haemorrhagic fever and 
Dengue shock syndrome
81
. 33.33%(2 cases) of coinfection had Dengue fever with 
warning signs and 16.66%(1 case) had Dengue fever without warnings. These serotypes 
were observed to circulate in this part of country in the current season of Dengue. 
However more molecular data were required to determine the true picture as this was 
only a small sample study. 
The treatment of Dengue virus infection is essentially supportive and 
symptomatic. No specific treatment is available and relies on WHO guidelines. Patients 
with mild symptoms were managed by maintaining oral hydration and monitored for 
warning signs. Patients with warning signs were managed with intravenous fluids after 
obtaining the haematocrit values and hydration was titrated accordingly. Patients with 
shock and haemorrhage were managed with intravenous crystalloid solution and blood 
transfusion. 
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SUMMARY 
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 The total number of patients with suspected Dengue in our hospital from August 
2016 to August 2017 was 6557, out of which 70.81%(4643) were seropositive. 
 A total of 150 consecutive serum samples were selected from August 2016 to 
August 2017, during peak Dengue season (August 2017) based on WHO clinical 
classification.All samples were subjected to NS1 microlisa, IgM capture ELISA 
and IgG capture ELISA(Panbio).Out of 150 samples, seropositivity was 78.67 
%(118) with 55.9%(66) primary Dengue and 44.1%(52) secondary Dengue 
infections.  
 IgM positivity was 9.3%(11), NS1+IgM was 9.3%(11), NS1+IgM+IgG was also 
9.3%(11), IgM+IgG was 33.99%(40) and only IgG was 0.85%(1). 
 NS1 antigen positivity was found in 55.93% (66) out of 118 patients, most of them 
had less than five days of fever. Nine patients out of these 66 showed NS1 
positivity (7.63%) on 9
th
 day of fever 
 males were affected more than females(1.2:1). 
 Commonly affected age group was11 to 20 years (32%). 
 More number of cases were seen between the months of July (23.4%) and August 
(19.5%). 
 Most common clinical symptom was high grade fever followed by joint pain. 
 Most commonly observed significant laboratory parameters were 
a)Thrombocytopenia (69.7% in primary Dengue, 90.4% in secondary Dengue)  b) 
Elevated liver enzymes (36.75% in primary Dengue, 59.6% in secondary Dengue). 
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 Molecular typing: Twenty two random samples had more than 50 NS1 antigen 
units, from which RNA was extracted by  1.QIA symphony DSP virus/pathogen 
midi kit, 2. QIA symphony DSP virus/pathogen mini kit, 3. Roche kit and 
4.QIAGEN kit 
 Out of which QIAsymphony midi kit yielded more concentration of RNA, which 
has been subjected to spectrophotometry to find out approximate concentration of 
RNA. All samples showed more than 40 µg/ml of RNA. Extracted RNA was 
subjected to MOBS buffer Electrophoresis using formaldehyde gel to detect and 
differentiate Dengue RNA from non-specific microRNA normally present in 
serum. 
  After this extracted RNA were subjected to one step Multiplex Nested RT-PCR  
by using following primers 
D1-5'-TCAATATGCTGAAACGCGCGAGAAACCG-3'-511 
D2-5'-TTGCACCAACAGTCAATGTCTTCAGGTTC-3'-511  
TS1-5'-CGTCTCAGTGATCCGGGGG-3'-482 (D1 & TS1),  
TS2-5'-CGCC ACAAGGGCCATGAACAG-3'-119 (D1 & TS2),  
TS3-5'-TAACATCATCATGAGACAGAGC-3'-290 (D1 &TS4 
TS4-5'-CTCTGTTGTCTTAAACAAGAGA-3'-392 (D1 & TS4) 
 
 Amplified products of RT-PCR were subjected to agarose gel electrophoresis for 
Dengue virus serotype identification. Fifteen out of 22 samples tested showed 
amplified product (68.18%). 
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 The most common serotype identified was DENV-3(11cases) followed by DENV-
2(10cases) among which  Co-infection  with DENV 2&3was seen in  6 cases , 
followed by DENV-3 alone in 5 cases and DENV-2 alone in 4 cases. 
  Fifty percent (3 cases) of DENV-2&3 coinfection was associated increase in 
disease severity leading to Dengue haemorrhagic fever and Dengue shock 
syndrome. 33.33%(2 cases) of coinfection had Dengue fever with warning signs 
and 16.66%(1 case) had Dengue fever without warning signs. 
 Eighty three percent (5 cases) of DENV-2&3 coinfection was primary Dengue. 
16.67%(1case) of coinfection was secondary Dengue. 
 DENV-3 and DENV-2 infection was associated with Dengue fever without 
warning signs. 
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CONCLUSION 
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Dengue fever is a rapidly evolving mosquito borne viral disease in our 
community. Early diagnosis of the infection by the detection of NS1 antigen coupled with 
capture ELISA followed by RT-PCR for serotype identification leads to proper treatment 
and reduction in morbidity and mortality. There are more primary infections than 
secondary infections. Little cross immunity exists between the serotypes offering less 
protection during cross infection leading to severe manifestations of the disease. The 
prevalent serotype of Dengue in this area was DEN-2&3 coinfection. Also infection with 
multiple serotypes leads to the emergence of recombinant strains.. 
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MATERIALS REQUIRED (REAGENTS USED): 
 
TBE Buffer: 
 Tris base(89.00)- 10.78g 
 Boric acid(89.00)- 5.5g 
 EDTA(0.5)- 3.72g 
 pH- 8.3 
10X buffer preparation: 
Mix the above contents in 1000 ml of milli Q water. 
1X buffer preparation: 
Nine hundred ml of milli Q water is added to 100 ml of 10X buffer. 
Ethidium bromide: 
10 mg/ml in distilled water. 
2% Agarose gel preparation: 
Two gram agarose powder, 50X TAE 2 ml, milli Q water 98 ml, ethidium bromide 
0.4µl. 
RNA Gel Run: 
Agarose 1.2g, miili Q water 90 ml, 10X MOBS buffer 10 ml, formaldehyde 1.8 
ml, ethidium bromide 0.341µl 
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ABBREVIATIONS 
 
DENV  Dengue virus 
DHF   Dengue haemorrhagic fever 
DSS   Dengue shock syndrome 
NS   Non-structural protein 
DC   Dendritic cells 
IL   Interleukin 
IFN   Interferon 
TNF   Tissue necrosis factor 
CTLA  Cytotoxic T-lymphocyte associated protein 
DC-SIGN Dendritic cell- Specific intercellular adhesion molecule-3-
Grabbing Non-integrin 
TGF Transforming  growth factor 
MMP Matrix metalloproteinases 
ICAM Intercellular adhesion molecule 
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor 
PCR Polymerase chain reaction 
HRP Horseradish peroxidase 
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